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The role of EHD2 in triple-negative breast cancer tumorigenesis and progression 
Timothy Alan Bielecki, Ph.D. 
University of Nebraska, 2017 
 
 
Supervisor: Hamid Band, M.D., Ph.D. 
Triple-negative breast cancer (TNBC) comprises 10%-15% of all breast cancer cases, yet 
is clinically challenging due to lack of targeted therapies which leads to higher mortality. 
Molecular subtyping has identified the most aggressive subclasses of breast cancer to be 
enriched in components of caveolae. While caveolae have been linked to many biological 
processes, their precise role in TNBC is still poorly understood. EHD2, a member of the 
C-terminal EPS15-Homology Domain-containing (EHD) protein family, has emerged as 
a new regulator of caveolae dynamics and is essential to maintain a stable membrane 
pool of caveolae. Studies in model cells demonstrate that caveolae facilitate repair of 
plasma membrane injuries incurred under stressful conditions. Importantly, new 
evidence suggests the invasiveness of tumor cells makes them vulnerable to plasma 
membrane injuries and hence a robust repair mechanism is essential to protect injured 
tumor cells from cell death.  
EHD2 is found to be highly expressed within the basal myoepithelial layer 
throughout mammary gland development. High EHD2 mRNA and protein expression 
was observed in human TNBC cell lines and positively correlated with Caveolin-1 and 
Caveolin-2 expression. Furthermore, by analyzing publicly available gene expression 
databases, we found that high expression of EHD2 mRNA correlated with lower 
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probability of survival in TNBC patients. This led us to hypothesize that EHD2 is a 
marker and crucial regulator of tumorigenicity in TNBC. Using a cohort of 840 highly-
annotated human breast cancer tissue samples, we discovered that high cytoplasmic 
expression of EHD2 marked TNBC cases, and served as a robust prognostic indicator of 
metastasis and lower patient survival. ShRNA-mediated knockdown of EHD2 in TNBC 
cell lines reduced invasiveness, growth under anchorage-independent conditions, and 
membrane repair ability in vitro. Using orthotopic implantation of human breast cancer 
cell lines in mouse mammary gland, we observed a dramatic abrogation of tumor 
growth and a reduction in metastasis of TNBC cell lines with EHD2 knockdown 
compared to their controls. These findings indicate that EHD2 is a novel clinical 
biomarker of poor prognosis in TNBC, and serves a novel role as a positive regulator of 
caveolae-dependent protection of plasma membrane against injury, enabling 
tumorigenicity and metastasis in TNBC. Our results support the potential of targeting 
EHD2 to develop therapeutic approaches against TNBC.  
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Chapter I: Introduction 
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I.1 Introduction 
 
Breast cancer affects more women than any other type of cancer and is the 
second leading cause of cancer-related deaths among women (Figure 1.1) (Siegel, Miller, 
and Jemal 2017). The disease is generally classified into three main molecular subtypes: 
estrogen receptor (ER) and/or progesterone receptor (PR) enriched (or ER+/PR+), human 
epidermal growth factor receptor (HER2) enriched (HER2+), and tumors without ER, 
PR, or HER2 overexpression, typically referred to as triple-negative (Figure 1.2). This 
classification system typically dictates the course of treatment for patients, and targeted 
therapies have been developed to successfully treat tumors with elevated ER/PR, and 
HER2 expression (Malhotra et al. 2010). Although triple-negative breast cancer (TNBC) 
comprises only 10%-15% of all breast cancer cases, it is clinically challenging due to its 
aggressiveness and current lack of targeted therapies (Marmé and Schneeweiss 2015). 
TNBC itself is not a single disease. In fact, TNBC is comprised of 5 distinct subclasses 
based on gene expression: Basal-like 1, Basal-like 2, luminal androgen receptor+, 
mesenchymal, mesenchymal stem like, and immunomodulatory (Lehmann et al. 2011). 
These efforts to further characterize TNBC have yielded a better understanding of this 
heterogeneous disease and a large list of potential targets for therapy. One such target, 
commonly expressed in the most aggressive subclasses, are cellular structures called 
caveolae (Yadav, Chanana, and Jhamb 2015; Pinilla et al. 2006; Neve et al. 2006).  
Caveolae, meaning “little caves” in Latin, are small (50-100 nm) plasma 
membrane-associated invaginations involved in endocytosis, lipid regulation, signaling 
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pathways, mechano-sensing, and membrane repair in many types of mammalian cells 
(Parton and del Pozo 2013; Martinez-Outschoorn, Sotgia, and Lisanti 2015; Lucas 
Pelkmans et al. 2004; L Pelkmans, Kartenbeck, and Helenius 2001; Okamoto et al. 1998; 
Blouin et al. 2010). While these caveolae-mediated processes are well understood in 
endothelial cells, adipocytes, and muscle cells, it’s unclear what roles caveolae play in 
TNBC. Caveolin-1, an essential structural component and marker of caveolae, has both 
oncogenic and tumor suppressor functions in many tumor types, including breast cancer 
(Patani et al. 2012). Despite the considerable evidence that it serves as a tumor 
suppressor in ER+/PR+ and HER2+ breast cancers (Nawaz et al. 1999; Mercier et al. 2009; 
Thomas et al. 2010; Engelman et al. 1998), caveolin-1 functions mainly as a tumor 
promoter in TNBC. Immuno-histochemical analysis of a 900-patient cohort revealed that 
caveolin-1 protein expression is associated with TNBC (Elsheikh et al. 2008). In fact, 
roughly 90% of metaplastic breast cancers, a type of TNBC that is highly aggressive and 
difficult to treat, have been shown to express caveolin-1 (Savage et al. 2007). 
Interestingly, the TNBC cell lines MDAMB231, Hs578t, and BT549 require caveolin-1 for 
invadopodia formation and extracellular degradation in vitro (Yamaguchi et al. 2009). 
Caveolin-1 and caveolin-2 are also highly expressed within the myoepithelial/basal layer 
of the normal mammary duct (Figure 1.3) (Savage et al. 2008). 
These findings suggest that caveolae are important for maintaining the 
aggressiveness of TNBC. However, more recent studies indicate that the central function 
of caveolae could be to protect the cell from plasma membrane stress and to repair 
membrane damage (Figure 1.4). Stretching of the plasma membrane from the 
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mechanical stress of osmotic shock causes caveolae to flatten and disassemble (Sinha et 
al. 2011). Furthermore, work in muscle cells has shown that caveolae cluster and 
regulate the repair of damaged regions of the plasma membrane (Corrotte et al. 2013). 
While much of this work has been based on in vitro experiments, there is also 
considerable evidence that the mechano-protective role of caveolae is physiologically 
relevant. In mouse endothelial, caveolae flatten and disassemble in response to increased 
membrane tension (Lo et al. 2015). The same study also found that vigorous muscle 
activity leads to cell damage in live zebrafish embryos lacking caveolae (Lo et al. 2015). 
Pharmacological stimulation of cardiac output increased mechanical stress, by 
increasing blood flow, on endothelial cells, resulting in the flattening of endothelial 
caveolae. Furthermore, depletion of caveolae made the endothelial cells more 
susceptible to acute plasma membrane damage (Cheng et al. 2015). Caveolin-1 has also 
been shown to be upregulated in TNBC cells subjected to fluid shear stress, indicating 
that caveolae serve a mechano-protective role during breast cancer metastasis (H. Yang 
et al. 2016).  
Another ubiquitous component of caveolae and regulator of plasma membrane 
repair is the Eps15 homology domain-containing 2 protein (EHD2). EHD2 is a member 
of the EHD-containing protein family of ATPases that are endocytic trafficking 
regulators similar to the dynamin family of GTPases (Figure 1.5) (George et al. 2007). 
Our lab and others have found that EHD2 is also highly expressed in caveolae-rich 
endothelial cells, adipocytes, and muscle cells (Figure 1.6)(Doherty et al. 2008; Sohn, 
Brick, and Tuan 2016; Gudmundsson et al. 2010; Marg et al. 2012). In muscle, EHD2 and 
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caveolae are required components of the plasma membrane repair process (Marg et al. 
2012; Lo et al. 2015). EHD2 dimerizes and forms oligomeric rings around lipids (Figure 
1.7) (Daumke et al. 2007). Contrary to the conventional endocytic trafficking role of the 
EHD family, EHD2 is specifically localized to the necks of stable caveolae at the plasma 
membrane and not involved in endocytosis or endosomal recycling (Figure 1.8) (Moren 
et al. 2012; Stoeber et al. 2012; Ludwig et al. 2013). Although EHD2 is not required for 
caveolae formation, EHD2 depletion increases caveolae mobility and caveolae budding, 
resulting in more dynamic caveolae (Stoeber et al. 2012; Mohan et al. 2015; Shah et al. 
2014).  
Despite these recent advances in our understanding of how EHD2 regulates 
caveolae stability and dynamics, there is little known about the involvement of EHD2 in 
caveolae-mediated membrane repair and protection processes. In muscle cells, EHD2 
binds to myoferlin and dysferlin, members of the ferlin family of proteins, which 
facilitate myoblast fusion and membrane repair, respectively (Doherty et al. 2008; Posey 
et al. 2011). The skeletal muscle membrane repair process has been even further 
characterized more recently and shown to involved annexins and EHD2 was shown to 
accumulate at the circumference of the repair patch (Figure 1.9) (Demonbreun et al. 
2016). Ferlin-dependent membrane repair is a Ca2+-dependent process that intimately 
involves caveolae (Cipta and Patel 2009). In endothelial cells, myoferlin binds to 
caveolin-1 during membrane fusion and fission events, and loss of caveolin-1 impairs 
membrane repair processes (Bernatchez et al. 2009). Recently, in vivo accelerated tumor 
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growth of human and murine carcinomas was found to rely on functional myoferlin-
dependent membrane repair processes (Leung et al. 2013).  
Recently, EHD2 has been implicated as a tumor suppressor in breast cancer 
(Yuhua Shi et al. 2015; X. Yang et al. 2015). Despite these findings, there is still no 
published literature on the role of EHD2 in TNBC, although previous studies have 
shown EHD2 mRNA expression to be significantly higher in caveolae-rich basal breast 
cancer cell lines and TNBC patient samples (Györffy et al. 2010; Neve et al. 2006). 
Understanding the regulatory role of EHD2 in caveolae-mediated membrane repair and 
protection processes in triple-negative breast cancer can provide a framework for 
potential new therapy targets that translate into novel treatment options for triple-
negative breast cancer patients. Based on our findings here, and previous reports of 
caveolae expression in TNBC and the role of EHD2 in regulating caveolae dynamics, we 
hypothesize that EHD2 regulates the dynamics and stability of caveolae required for 
plasma membrane repair and protection in triple-negative breast cancer. We also 
hypothesize that EHD2-mediated regulation of caveolae is essential for the most 
aggressive and difficult to treat types of TNBC. 
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I.2 Figures 
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Figure 1.1 
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Figure 1.1 Breast cancer is the most common cancer among women. Ten leading cancer 
types for the estimated new cancer cases and deaths by sex, United States, 2017, are 
shown on this table. Estimates are rounded to the nearest 10 and cases exclude basal cell 
and squamous cell skin cancers and in situ carcinoma except urinary bladder. 
Used with permission from Siegel et al. (Siegel, Miller, and Jemal 2017) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
 
 
Figure 1.2 
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Figure 1.2 Breast cancer pathogenesis and histologic vs. molecular subtypes. The 
clinical breast cancer molecular subtypes (luminal A, luminal B, HER2+, and triple-
negative) are defined by the phenotypes and gene expression patterns they share with 
normal epithelial cells in the mammary duct. Specifically, luminal subtypes share 
characteristics with luminal cells and the triple-negative subtype shares characteristics 
with basal/myoepithelial cells. 
Used with permission from McMaster Pathophysiology Review, 2012 
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Figure 1.3 
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Figure 1.3. Analysis of caveolin 1 and 2 expression in normal breast by 
immunofluorescence. Normal breast ducts (A and B) and terminal duct-lobular units (C 
and D) display strong expression of caveolin 1 (A and C, green) and 2 (B and D, green) 
in myoepithelial cells, which also co-express p63 (A, B, C and D, red). Note that within 
breast ducts and lobules, caveolins 1 and 2 are expressed in similar cell populations (i.e., 
myoepithelial cells). In addition, caveolin are expressed in fibroblasts and endothelial 
cells. In E and F, please note the co-expression of caveolin 2 (E and F, green) and α-
smooth muscle actin (E and F, red) in normal breast myoepithelial cells. In vessels, 
asmooth muscle actin is expressed in pericytes (E and F, red, arrow), whereas caveolin 2 
is expressed in endothelial cells (E and F, green, arrowheads)  
Used with permission from (Savage et al. 2008) 
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Figure 1.4 
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Figure 1.4. Models of how caveolae may protect the plasma membrane from damage. 
(A) Increased membrane tension results in cavin 1-associated coats detaching from the 
membrane. Consequently, caveolae flatten, which increases the surface area and 
prevents membrane rupture. Disassembled complexes contain subpopulations of cavin 1 
alone or bound to either cavin 2 or cavin 3. (B) Wounding of the membrane results in the 
formation and clustering of caveolae at the site of damage. The lesion is then removed 
by internalization of the caveolae, which reseals the membrane. 
Used with permission from (Cheng and Nichols 2016). 
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Figure 1.5 
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Figure 1.5. Structure and regions of EHD2. a, Domain structure of EHD proteins 
(numbering from mouse EHD2 amino acids). b, Helical domain. Organizes scaffolding 
with dimeric G-domain to help form scissor shape c, G-domain. Mediates 
oligomerization and contains nucleotide-binding site similar to the G-domain of 
dynamin. d, EH-domain. The EH-domain interacts with proteins containing Asn-Pro-
Phe (NPF) motifs. e, Ribbon-type presentation of the EHD2 dimer (PDB code 2QPT). 
One molecule is colored according to the secondary structure (helices in red, β-strands 
in green) and the other according to the domain structure (see Fig. 1a). GPF and NPF 
motifs are indicated.  
Adapted and used with permission from Daumke et al. (Daumke et al. 2007) 
 
 
 
 
 
 
 
 
19 
 
Figure 1.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
20 
 
Figure 1.6. EHD protein expression in normal mouse tissues. An 18 week-old male and 
female C57BL/6 mouse were sacrificed and organs were removed and lysed in tissue 
lysis buffer. Aliquots of 100 µg tissue lysate were separated using 8% SDS-PAGE and a 
Western blot was performed using antibodies raised against human EHD proteins. The 
membrane was serially stripped and reprobed beginning with both EHD1 and EHD4, 
followed by EHD2, EHD3 and Hsc70 antibodies. The * denotes bands that bled through 
from the previous blot following stripping. Differential mobility of Hsc70 may represent 
tissue specific isoforms. Blots shown have exposure times of less than 10 seconds, upon 
longer exposures, most EHD proteins can be seen in each organ shown. Relative 
molecular weight (MW) markers are indicated in kiloDaltons (kD). As a loading control, 
Hsc70 was blotted. M. gland – mammary gland 
Used with permission from (George et al. 2007) 
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Figure 1.7 
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Figure 1.7. Schematic model illustrating the proposed steps involved in the 
mechanistic cycle of EHD2. Binding of ATP nucleotide enables membrane insertion in 
the open conformation. ATP hydrolysis enables detachment of the protein from the 
membrane. These two steps allow EHD2 to oligomerize when bound to the membranes, 
but not in solution. The energy that is necessary to deform the membrane is defined by 
the bending modulus (∼12 kcal/mol for a typical lipid bilayer) (30). It is interesting to 
note that this energy appears to be drawn from the association of EHD2 into membrane-
bound oligomers and not from ATP hydrolysis. Thus, the hydrolysis may primarily 
control the kinetics of the dissociation of the protein scaffold, which is important for a 
tight regulation of the process. 
Used with permission from (Hoernke et al. 2017) 
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Figure 1.8 
 
 
 
  
 
 
 
 
 
  
24 
 
Figure 1.8. A model on the role of oligomer formation and the ATP cycle in EHD2 
association with caveolae and dynamic exchange. (1) Newly synthesized EHD2 dimers 
bind ATP and are subsequently targeted to the plasma membrane via ionic interactions 
with negatively charged lipids. (2) Upon lipid binding, EHD2 dimers assemble into 60–
75S oligomers via interactions of EH domain and KPF/NPF motifs in adjacent EHD2 
dimers. (3) Association of EHD2 complexes with caveolae requires ATP hydrolysis, 
which may be stimulated at caveolae. (4) EHD2 proteins undergo dynamic exchange at 
caveolae, which requires a new cycle of ATP binding and hydrolysis. EHD2 mediates a 
link to actin fibers that run in close proximity to caveolae. 
Used with permission from (Stoeber et al. 2012) 
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Figure 1.9 
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Figure 1.9. Model of membrane repair. Upon plasma membrane injury, repair proteins 
localize to the site of damage and actin reorganizes, facilitating membrane repair. 
Annexins A1, A2, and A6 form a repair cap at the membrane lesion. Dysferlin (DYSF), 
MG53, BIN1, and EHD participate in forming a shoulder that abuts this repair cap. PIP2 
and PS localize adjacent to the repair cap at the shoulder. 
Used with permission from (Demonbreun et al. 2016) 
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II.1 Materials and Methods 
Cell culture: 
All breast cancer cell lines were obtained from ATCC and cultured in complete α-MEM 
medium with 10% fetal bovine serum, 10 mM HEPES, 1 mM each of sodium pyruvate, 
nonessential amino acids and L-glutamine, 50 µM 2-ME, and 1% penicillin/ 
streptomycin (Life Technologies, Carlsbad, CA). The TNBC cell lines BT549 and HS578t 
were cultured in α-MEM medium supplemented as above and with 1 µg/mL 
hydrocortisone and 12.5 ng/mL epidermal growth factor (Sigma-Aldrich, St. Louis, MO). 
For retroviral overexpression of control and EHD2 shRNA, HEK-293T cells were 
transfected with pQCXIX-RT3GEP vectors harboring control shRNA or EHD2 shRNAs 
(Fellmann et al. 2013) together with packaging vectors, and supernatants used to infect 
breast cancer cell lines followed by selection in puromycin. Cell lines were regularly 
tested for mycoplasma. Cell lines were not continuously cultured for >3 months. 
Reagents 
Bovine serum albumin (cat. # A7906-100G), paraformaldehyde (cat. # 158127-500G), 
sodium orthovanadate (Na3VO4, cat # S6508-50G), sodium deoxycholate (cat # D6750-
100G), and Triton X-100 (cat. # 93418) were from Sigma-Aldrich (St. Louis, MO). Hema 
staining solutions (cat. # 23-123919), sodium fluoride (NaF, cat # S299-500), sodium 
chloride (NaCl, cat # S271-10), and Tris (cat BP152-5) were from Fisher Chemicals. 
EDTA-free protease inhibitor cocktail (cat. # 4693159001) was from Roche. ECL 
development reagent (cat. # 32106), BSA for bicinchoninic acid assay (cat # 23209), and 
PMSF (cat # 36978) were from Thermo-Scientific. Penicillin/streptomycin (cat. # 15140-
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122) and fetal bovine serum (FBS) (cat. # 10427-028; lot # 1662765A120-01) were from Life 
Technologies. Alpha-MEM (cat. # SH30265.01) and DMEM/F12 (cat. # SHO30023.01) 
were from GE Life Sciences.  
Antibodies for western blot 
Anti-HSC70 (cat. #sc-7298) and anti-caveolin-1 (cat # sc-894) were from Santa Cruz 
Biotechnology. In-house generated Protein G-purified rabbit polyclonal anti-EHD1 
antibody, and rabbit anti-EHD2, anti-EHD3 and anti-EHD4 antisera were used as 
described previously (Rainey et al., 2010).  Secondary antibodies for immunoblotting 
included horseradish peroxidase (HRP)-conjugated Protein A or HRP-conjugated rabbit 
anti-mouse antibody (Invitrogen, Carlsbad, CA). 
Antibodies for immunofluorescence (IF) 
Anti-caveolin-1 (cat. # sc-53564) was from Santa Cruz Biotechnology; anti-EHD1 (cat. # 
ab109311) was from Abcam. Affinity-purified rabbit polyclonal rabbit anti-EHD2 was 
used as described previously (Rainey et al., 2010). Secondary fluorochrome-conjugated 
antibodies were from Life Technologies. 
Mouse models 
Ehd1-null mice were maintained on mixed 129; B6 background (Rainey et al. 2010). 
Single nucleotide polymorphism (SNP) analysis (DartMouse, Lebanon, NH) revealed 
these to have ~70% contribution from the C57BL/6 genome (Figure 2.1). Breeders were 
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maintained on high-fat chow (# 2019, Harlan Laboratories Inc., Madison, WI). Genomic 
DNA was extracted from adult tail tips with KAPA genotyping kits (KAPA Biosystems). 
For the mammary gland developmental timepoint experiments, mating was set up in 
the evenings, and vaginal plugs were detected the following morning. The noon of the 
day of vaginal plug detection was considered Pregnancy day 0.5. Female mice were 
euthanized by CO2 asphyxiation at the indicated time points followed by cervical 
dislocation, and whole inguinal mammary glands were harvested. Mammary glands 
were fixed at RT in 10% neutral-buffered formalin (NBF) for 48 hours, transferred to 70% 
ethanol prior to paraffin embedding, and sectioned at 4-6 µm. Sections were stained 
with hematoxylin and eosin (H&E). IHC for anti-EHD2 was performed according to the 
IHC protocol. Brightfield images were captured using an EVOS FL Auto microscope. 
Cell Lysates: Cells were either lysed in RIPA lysis buffer (50 mM Tris pH 7.5, 150 mM 
NaCl, 1% Triton-X-100, 0.05% deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 10 mM NaF, and 1 mM sodium orthovanadate) or Triton-X-100 lysis 
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% Triton-X-100, 1 mM PMSF, 10 mM NaF, 
and 1 mM sodium orthovanadate)(2). Lysates were rocked at 4°C for at least 1 hour or 
frozen at -80°C and then centrifuged at 13,000 rpm for 20 minutes at 4°C and the 
supernatants assayed for protein concentration using the BCA assay kit (Thermo Fisher 
Scientific, Rockford, IL) or the Bradford assay (Bio-Rad Laboratories, Hercules, CA). 
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Immunoblotting 
Immunoblotting/Western blotting was performed as described (Rainey et al. 2010). 
Briefly, cells were washed with ice-cold PBS and lysed in ice-cold RIPA lysis buffer or 
Triton X-100 lysis buffer. The lysates were vortexed, centrifuged at 13,000 rpm for 30 
minutes at 4o C, and supernatants collected. Protein quantification was done by using a 
Thermo Scientific-Pierce Bicinchoninic acid (BCA) assay (cat. # 23225). 40 µg of lysate 
protein per sample was resolved by SDS/PAGE and transferred to a PVDF membrane 
(Millipore, cat. # IPVH00010). The membranes were blocked in TBS-0.1% Tween 20 (BIO-
RAD, cat. # 161-0781) with 5% Bovine Serum Albumin (BSA) with 0.05% sodium azide, 
incubated with the appropriate primary antibodies diluted in TBS-0.1% Tween 20 
overnight at 4°C. Next, membranes were washed in TBS-0.1% Tween 20 (three times for 
ten minutes) followed by a one-hour incubation with HRP-conjugated secondary 
antibody at room temperature. The membrane was washed in TBS-0.1% Tween 20 (three 
times for ten minutes) and ECL-based detection performed. 
Immunofluorescence (IF) 
Cellular immunofluorescence was performed, as previously described (Bailey et al. 
2014) with minor modifications. Cells were cultured on glass coverslips and fixed with 
4% PFA/PBS for 10 minutes.  The cells were then blocked with 5% BSA/PBS for 60 
minutes and incubated with primary antibodies in 5% BSA/PBS overnight. Cells were 
then washed with PBS (three times), incubated with the appropriate fluorochrome-
conjugated secondary antibody for 45 minutes at room temperature (RT), washed and 
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mounted using VECTASHEILD mounting medium (Vector Laboratories, Cat. # H-1400 
and H-1500). Images were acquired using a Zeiss 710 Meta Confocal Laser Scanning 
microscope (Carl Zeiss) using a 4x, 10x, 20x, or 63× objective with a numerical aperture 
of 1.0 and appropriate filters. Merged fluorescence pictures were generated and 
analyzed using ZEN® 2012 software from Carl Zeiss. 
For tissue staining, rehydrated tissue sections were boiled in antigen unmasking 
solution (H-3300, Vector Laboratories, Burlingame, CA) in a microwave for 20 min, 
slides were cooled, washed once in PBS, and blocked in heat-inactivated 10% FBS 
(SH30910.03, HyClone Laboratories, Logan, UT) for one hour at room temperature (RT). 
Primary antibodies diluted in blocking buffer were added overnight at 4°C (except EHD 
antibody staining, which was done at RT for an hour), slides were washed 3 times with 
PBS followed by incubation with Alexa Fluor 488 or 594-conjugated donkey anti-rabbit 
or anti-mouse secondary antibodies (1:200; Invitrogen, Carlsbad, CA) for one hour at RT 
in the dark. For negative controls, sections were incubated in the blocking buffer 
without the primary antibody. Nuclei were visualized with DAPI in antifade mounting 
medium (ProLong® Gold Antifade mountant, Invitrogen, Carlsbad, CA). Fluorescent 
images were captured on a Zeiss LSM-710 confocal microscope. Images were processed 
using Adobe Photoshop CC software. For presentation, signal intensities were adjusted 
equally for brightness and contrast between control and test images. 
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Transfection Reagents and Plasmids 
 XtremeGENE 9 transfection reagent was from Roche Applied Science (Indianapolis, IN). 
A pQCXIX-RT3GEP (Fellmann et al. 2013) shRNA construct for scrambled shRNA or 
EHD2-targeted shRNA was custom-made through a commercial vendor (Mirimus) 
(Figure 2.1). 
Trans-well invasion assays 
The cells were seeded in the top chamber of trans-well chambers with 8 µm pore size 
nitrocellulose filters (Corning) in serum-free medium. Medium containing 10% FBS 
served as a chemoattractant in the lower chamber. The membranes were coated with 1:2 
diluted Matrigel (BD Biosciences) before seeding the cells. After 22 h, the cells on the 
upper side of the membrane were removed by scraping with cotton swabs, while those 
on the lower side were fixed with methanol, stained with HEMA solutions and cells 
were counted. The migrated cells from the whole well were enumerated using Image J 
(NIH, MD). All experiments were done in triplicates, and repeated three times. 
Orthotopic xenograft tumorigenesis 
 5 x 106 cells mixed with 0.2 ml Matrigel (BD Biosciences) were implanted in the 
mammary fat pad of 4 to 6 week-old non-pregnant female nude mice (Figure 2.2) (The 
Jackson Laboratory). Three days prior to cell implantation, the mice were primed with a 
subcutaneous estrogen pellet (0.72 mg/ 60 day pellets; Innovative Research of America, 
Sarasota, FL) and tumor growth monitored weekly for 12 to 14 weeks. After euthanasia, 
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tumors were imaged, and formalin-fixed and paraffin-embedded for further analyses. 
Tumor dimensions were measured with Vernier calipers and tumor volume calculated 
as length x width x depth/2.  Mice were euthanized when control tumors reached 2 cm3 
in volume or showed signs of ill health, as per institutional IACUC guidelines. At the 
end of the experiment, the tumor as well as liver and lung are resected, formalin-fixed 
and paraffin-embedded for further analyses.  
Human and animal subjects 
The procurement and use of human tissues were approved by the Ethics Committee of 
the University of Nottingham where the tissues are archived under the direction of our 
collaborator Dr. Emad Rakha (University of Nottigham Hospital, Department of 
Pathology, Breast Unit). Mouse studies were pre-approved by the UNMC Institutional 
Review Board (IRB) Committee, in compliance with Federal and State guidelines. 
IHC analysis of breast cancer tissue microarrays   
Tissue microarrays (TMAs) corresponding to a well-annotated 971 breast cancer patient 
cohort at the University of Nottingham Hospital Breast Unit were analyzed by IHC 
staining with a previously described anti-rabbit EHD2 antibody (Rainey et al., 2010) that 
was further validated (Figure 3.3). Of the whole series (840 cases), 759 were informative. 
The expression of EHD2 was detected in the cytoplasm and/or nucleus of the malignant 
cells while, in the normal parenchymal element its expression was noted in the nuclei of 
epithelial cells only. For statistical analysis, expression was dichotomized using cutoff 
points that were selected based on histogram distribution. The cutoff points were 
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selected using median and X-tile software as follows: a H-score of zero for nuclear EHD2 
and H-score of 50 for cytoplasmic EHD2 expression. Statistical analysis was performed 
by using the SPSS IBM 22 statistical software. The relationship between nuclear and 
cytoplasmic EHD2 expression and different clinicopathological variables was assessed 
using Chi square-test. Survival curves were obtained using Kaplan–Meier method for 
outcome estimation and significance determined using the log-rank test.  Two-tailed P-
values less than 0.05 we re considered significant. 
Anchorage-independent growth assay 
 Three thousand cells were seeded in 0.3% soft agar on top of 0.6% soft agar layer in 6-
well plates. After two weeks, cells were stained with crystal violet and imaged under a 
phase contrast microscope. The colonies in the entire wells were enumerated using 
Image J (NIH, MD). All experiments were done in triplicates, and repeated three times. 
Tumor-sphere assay 
Cells were re-suspended in DMEM/F12 (cat. # SH30023.01, GE Lifesciences) media 
supplemented with 2mM L-glutamine, 100U/ml penicillin/streptomycin, 20ng/ml EGF 
(sigma), 10 ng/ml FGF (R&D Systems) and 1x B27 supplement (Gibco), and seeded at 
100,000 cells/well into poly-HEMA coated 6-well plates. After one week, tumor-spheres 
were imaged under a phase contrast microscope. Tumorspheres greater than 40 µm in 
diameter were quantified as previously described (Shaw et al. 2012), using Image J (NIH, 
MD). All experiments were done in triplicates, and repeated three times. 
36 
 
Membrane repair assay 
 Cells were grown on coverslips and washed with PBS + 2mM Ca2+ before transferring to 
phenol red free HBSS + 2mM Ca2+ containing 2 mg/ml lysine fixable 10-kDa CascadeBlue 
dextran. Glass beads of about 20 mg (425-600 µm, Sigma) were sprinkled onto the cells 
and the beads were rolled gently 10-12 times over the cells to induce plasma membrane 
wounds. After wounding the coverslips were incubated as such at 37°C for 5 min. 
Following one wash with PBS + 2mM Ca2+ buffer, cells were incubated with prewarmed 
phenol red-free HBSS + 2 mM Ca2+ containing 2 mg/ml lysine fixable 10-kDA TRITC 
dextran at 37°C for 5 min. The coverslips were then washed in PBS twice and fixed in 4% 
PFA. The number of CascadeBlue-positive (total wounded cells) and TRITC-positive 
(wounded cells which have not resealed) were counted in 20 fields in duplicate. Cells 
were imaged using an EVOS FL Auto inverted microscope with 10x objective, using 
DAPI and TexasRed lightcubes. The number of wounded cells that failed to reseal were 
expressed as a percentage of the total wounded cells, as previously described (Defour, 
Sreetama, and Jaiswal 2014). 
Matrigel spheroid assay 
Cells were re-suspended as a single cell suspension in media containing 50% Matrigel 
and seeded at 2,000 cells/well on top of a base layer of Matrigel in an 8-well chamber 
slide. TNBC cell spheroids were allowed to grow for 7 days and then imaged and 
quantified. Quantification of invasive spheroids was performed by comparing the 
number of spheroids with invadopodia to the total number of spheroids. Over 100 total 
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spheroids were counted per well and all experiments were done in triplicates and 
repeated three times. 
Statistics 
P-values were calculated by using an unpaired Student’s t-test and the threshold of 
significance was p<0.05. Data is shown graphically as mean ± SEM (error bars). 
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Figure 2.1  
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Figure 2.1 Retroviral plasmid for EHD2 shRNA. a, Retroviral vector used to form 
EHD2 shRNA. b, Constitutive shRNA expression vector obtained from Mirimus, Inc. 
The shRNA is embedded in an enhanced miR-30 backbone termed miR-E. 
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Figure 2.2  
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Figure 2.2 Orthotopic injection of breast cancer cells.  TNBC cell lines (MDA-MB-231, 
BT549, or  HS578T) with EHD2 or control shRNA were concentrated into 5 x 106 cells per 
100uL suspensions of 50% Matrigel. Cell suspensions were implanted into the inguinal 
mammary gland of 4 to 6-week old non-pregnant female nude mice. Tumors were 
detected 3 weeks after implantation and followed for 11-13 weeks. 
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Chapter III: Results 
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III.1 Results 
A. EHD2 and caveolin-1 are expressed within the myoepithelial/basal layer of 
the mammary duct 
As described previously (George et al. 2007), EHD protein expression is 
differential throughout many murine tissues (Figure 1). Although EHD2 protein 
expression is high in western blots of total murine mammary gland lysates, we sought to 
further characterize the exact the expression and location of EHDs within this tissue. We 
initiated studies by first reconfirming the expression pattern of EHDs within total 
mammary gland lysate of wild type female C57BL/6 mice (Figure 3.1 A).  Our results 
showed that EHD2 was indeed the highest expressed member of the EHD family of 
proteins within the murine mammary gland. Consistent with previous analysis (George 
et al. 2007), EHD 1 and EHD4 were both expressed while EHD3 was not observed.  
We next sought to determine the localization of the EHDs expressed within the 
mammary gland. To accomplish this, we performed confocal immunofluoresence on 
formalin-fixed, paraffin-embedded (FFPE) mammary gland sections from twelve-week-
old female C57BL/6 mice. Due to issues with antibody specificity, the localization of EHD4 
could not be accurately observed. However, we found that EHD2 was specifically and 
consistently expressed in the myoepithelial/basal layer of the mammary duct and the 
adipocytes of the surrounding stroma (Figure 3.1 B). EHD1, on the other hand, was barely 
detectable within the mammary duct and surrounding stroma, except for the subcapsular 
sinus region of the mammary lymph node (Figure 3.2 A, Figure 3.2 B). Although striking, 
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these findings make sense given that the subcapsular sinus region contains CD-169+ 
macrophages with high expression of CSF-1 receptor(Shiota et al. 2016), and that EHD1 
plays a crucial role in regulating the endocytic trafficking of CSF-1 receptor within 
macrophages(Cypher et al. 2016).  
To confirm the specificity of our EHD2 antibody, we compared the wild type 
mammary gland expression with a newly developed EHD2-/- C57BL/6 mouse developed 
by GenOway. Western blot and confocal immunofluoresence confirmed that our EHD2 
antibody was indeed specific (Figure 3.3 A, Figure 3.3 B). Interestingly, knockout of EHD2 
in the EHD2-/- female mice led to an increase in EHD1 expression within compartments 
typically expressing EHD2 (Figure 3.3 C). This suggests that EHD1 serves a functionally 
redundant role to EHD2 in these specific mammary ductal compartments, consistent with 
previous literature regarding the functionally redundant roles of EHDs in other tissues 
(Rainey et al. 2010; Sengupta et al. 2009; George et al. 2011). Additionally, the upregulation 
of EHD1 in response to EHD2 knockout may explain why EHD2-/- mice do not exhibit any 
overt phenotype (data not shown). Despite these EHD1 findings, we elected to focus on 
EHD2 expression within the mammary gland.  
While EHD2 was highly expressed within the myoepithelial/basal layer of 12-
week old mice, we sought to confirm its localization in human tissue. Using human breast 
tissue sections, we performed immunohistochemical staining to confirm EHD2 
localization in human mammary ducts is consistent with what we observed in mice. We 
found that EHD2 was indeed localized to the myoepithelial/basal layer in the mammary 
duct of human breast tissue (Figure 3.4 A).  
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Considering the highly dynamic nature of the mammary gland (Inman et al. 2015), 
we decided to investigate the consistency of EHD2 expression and localization during 
different points of mammary gland development.  Using immunohistochemical staining, 
we found that EHD2 was consistently localized to the myoepithelial/basal layer of the 
murine mammary duct throughout puberty, adulthood, pregnancy, lactation, and 
involution (Figure 3.4 B).  
 Given the established role of EHD2 in caveolar dynamics (Stoeber et al. 2012; 
Moren et al. 2012), we suspected that the specific and consistent expression of EHD2 
within the myoepithelial/basal layer of the mammary duct is relevant to caveolae function 
within these compartments. Accordingly, we found that caveolin-1 expression is also high 
within these same compartments (Figure 3.5 A) but knockout of EHD2 did not alter 
caveolin-1 levels (Figure 3.5 B), consistent with previous literature (Mercier et al. 2009; 
Aoki et al. 2011; Pinilla et al. 2006; Stoeber et al. 2012).   
 
B. EHD2 and caveolin-1 are co-expressed in Basal B and Triple-Negative 
breast cancer cell lines 
We then selected a large panel of human breast cancer cells and performed 
biochemical analysis to determine the protein expression of EHD2. We found that EHD2 
was mainly expressed in TNBC cell lines and largely absent from the ER+/PR+ and HER2+ 
cell lines (Figure 3.6 A). EHD2 expression was also observed in the basal non-malignant 
mammary epithelial cell lines, 76Ntert and MCF10a. 
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Using the online database Gene expression-based Outcome for Breast cancer 
Online (GOBO) (Ringnér et al. 2011), we found that EHD2 mRNA expression was 
significantly higher in Basal B breast cancer lines compared to the Basal A and HER2+ cell 
lines in the panel (Figure 3.6 B). Moreover, caveolin-1 mRNA expression was also 
significantly higher in the Basal B cell lines (Figure 3.6 C). The Basal B subtype is the most 
invasive breast cancer subtype and is are considered to be triple-negative (Neve et al. 
2006).  When analyzing individual cell lines by the same method, we identified cell lines 
with high EHD2 mRNA expression (Figure 3.7 A) and high co-expression of EHD2 and 
caveolin-1 mRNA within the Basal B subtype (Figure 3.7 B).  
Next, we selected a few cell lines to determine if EHD2 mRNA levels correlate with 
EHD2 protein levels. We found that EHD2 mRNA correlates with protein levels in our 
selected breast cancer cell lines (Figure 3.8 A), and EHD2 protein was high in our selected 
Basal B cell lines (Figure 3.8 B). Since we are studying the role of EHD2 in regulating 
plasma membrane associated caveolae, we used confocal microscopy to determine in our 
selected breast cancer cell lines expressed EHD2 at the cell membrane. We observed the 
majority of EHD2 localized at the plasma membrane in our EHD2 positive cell lines 
(Figure 3.8 C). To confirm the in vitro expression of EHD2 in our selected TNBC cell lines, 
we injected MDAMB468, Hs578t, or MCF7 cells into the inguinal mammary glands of 
NSG mice and harvested the tumors after 6 weeks. We then used immunohistochemical 
analysis to confirm that EHD2 was expressed in the tumors generated from the Basal B 
cell line (Hs578t) and not in the basal A (MDAMB468) or luminal cell line (MCF7) (Figure 
3.8 D). 
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Once we determined the extent of EHD2 expression within our selection of human 
breast cancer cell lines, we sought to determine the extent of EHD2 co-expression and co-
localization with caveolin-1. Although the regulation of caveolae via EHD2 is well 
established in the literature (Briand et al. 2014; Stoeber et al. 2012; Morén et al. 2012; 
Hansen, Howard, and Nichols 2011; Simone, Naslavsky, and Caplan 2014), there is 
nothing published that demonstrates the relationship between EHD2 and caveolae in 
breast cancer or the mammary gland. Moreover, the role of caveolae in breast cancer is 
unclear and seems to function as a tumor promoter in some subtypes while serving as a 
tumor suppressor in others (Feldman et al. 2015; Savage et al. 2008; Mercier and Lisanti 
2012). Since caveolin-1 is the essential structural protein of caveolae, we used a large panel 
of breast cancer cell lines to ascertain the level of EHD2 and caveolin-1 co-expression. We 
found EHD2 and caveolin-1 protein expression to be mutually exclusive throughout our 
selected cell lines (Figure 3.9 A), indicating that EHD2 serves an important role for 
caveolae in breast cancer. Since EHD2 tends to be more highly expressed in TNBC and 
caveolae expression is believed to serve as a tumor promoter in TNBC (Elsheikh et al. 
2008), we performed confocal immunofluorescence on EHD2-expressing TNBC cell lines 
to determine the extent of co-localization. We observed near perfect co-localization of 
EHD2 and caveolin-1 in MDA-MB-231, BT549, and Hs578t cell lines (Figure 3.9 B), 
showing that EHD2 is localizing to caveolae in breast cancer cell lines for the first time.  
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C. EHD2 and caveolin expression is associated with lower survival in patients 
with triple-negative breast cancer 
After we determined that mRNA expression of EHD2 and caveolin-1 correlates to 
protein expression in human breast cancer cell lines, we sought to analyze co-expression 
of EHD2 mRNA with caveolin-1 (CAV1) and caveolin-2 (CAV2) mRNA in human breast 
cancer samples. We used bc-GenExMiner (Jézéquel et al. 2013; Jézéquel et al. 2012), an 
online database of mRNA expression from over 5,000 breast cancer samples, to determine 
the Pearson’s pairwise correlation for EHD2 mRNA in relation to CAV1 and CAV2 
expression across all tumor samples (Figure 3.10 A). We found EHD2 mRNA expression 
to be significantly positively correlated with CAV1 (Figure 3.10 B) and CAV2 (Figure 3.10 
C).  
Since we observed that EHD2 mRNA is positively correlated with CAV1 and 
CAV2 mRNA in breast cancer cases, we next examined the effect of EHD2, CAV1, and 
CAV2 mRNA expression in relation to survival of human breast cancer patients. Using 
KM-plotter (Györffy et al. 2010), an online database of mRNA expression levels in relation 
to survival in breast cancer patients, we found that high EHD2 mRNA expression was 
significantly associated with lower probability of survival in patients with basal tumors, 
but not across all breast cancer cases (Figure 3.11 A). Interestingly, the same pattern in 
survival was seen for CAV1 (Figure 3.11 B) and CAV2 (Figure 3.11 C) mRNA expression. 
Using GOBO (Ringnér et al. 2011), we were able to screen for probability of survival for 
breast cancer patients with either combined low or combined high mRNA expression for 
EHD2, CAV1, and CAV2. Once again, we found that high combined EHD2, CAV1, and 
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CAV2 mRNA expression was significantly associated with lower probability of distant 
metastasis-free survival (DMFS) in patients with basal tumors, but not in across all patient 
tumor samples (Figure 3.12 A and Figure 3.12 B).  
 Although we determined mRNA expression to be a good indication of EHD2 
protein expression in breast cancer cell lines, we wanted to determine if EHD2 protein 
expression was in fact associated with TNBC and caveolin expression in patient cases. In 
a blind study, we performed immunohistochemical staining using an anti-EHD2 on a 
tumor microarray (TMA) of a well-characterized cohort of 880 breast cancer patient 
samples that had previously been assessed for caveolin-1 and caveolin-2 protein 
expression(Elsheikh et al. 2008). The stained slides were then scored by pathologists and 
categorized for expression levels of nuclear and cytoplasmic EHD2 (Figure 3.13 A). The 
protein expression and localization scores were then compared to breast cancer specific 
survival (BCSS) for the patient cohort (Figure 3.13 B). High cytoplasmic expression was 
significantly associated with lower probability of survival for all cases and markers for 
poorer prognosis (Table 3.1). Interestingly, high nuclear expression was significantly 
associated with higher probability of survival and markers for better prognosis (Table 3.1). 
The unexpected nuclear expression of EHD2 and its association with higher survival 
could explain the previously observed discrepancy in survival probability between all 
tumor cases and basal tumors with regards to mRNA expression. In fact, when the 
samples are scored for only high or low/negative cytoplasmic EHD2 expression (Figure 
3.14 A), high EHD2 expression is significantly associated with TNBC (Figure 3.14 B) and 
lower survival (Figure 3.14 C). Conversely, nuclear expression is associated with luminal 
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markers (Table 3.1).  Consistent with our previous findings in breast cancer cell lines and 
mRNA expression data of human breast cancer patients, high EHD2 cytoplasmic 
expression is associated with Caveolin-2 expression (Table 3.2). Despite the interesting 
finding regarding EHD2 expression within the nucleus, we decided to focus on 
cytoplasmic EHD2 expression and its association with TNBC. 
 
D. shRNA-mediated knockdown of EHD2 leads to reduced tumorigenicity 
and invasiveness of Triple-negative breast cancer in vitro and in vivo 
 Using retroviral transduction, we generated three TNBC cell lines (MDA-MB-231, 
BT549, and Hs578t) with stable EHD2 shRNA and control shRNA (Figure 3.15 A). We did 
not find any significant change in proliferation in TNBC cells with EHD2 shRNA (Figure 
3.15 B). However, we found significant reduction in invasion in TNBC cells with EHD2 
shRNA compared to controls (Figure 3.15 C). Additionally, cells with EHD2 shRNA had 
lower tumorigenicity, as indicated by fewer soft-agar colonies (Figure 3.16) and fewer 
tumorspheres in non-adherent conditions (Figure 3.17). 
 Next, we sought to examine the effect of EHD2 depletion in TNBC tumors in vivo. 
We performed xenograft injections into the inguinal mammary gland of 4-week-old nude 
mice. After two weeks, palpable tumors were observed in all mice. The tumor volume of 
each mouse was measure every week until the study was terminated in week eleven. We 
found that EHD2 knockdown dramatically halted tumor volume and progression, 
compared to mice with control shRNA in BT549 (Figure 3.18 A and Figure 3.18 B) and 
HS578t tumors (Figure 3.19 A and Figure 3.19 B). Additionally, EHD2 knockdown tumors 
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had a decrease in proliferation, per immunohistochemical staining of proliferative marker 
Ki-67 (Figure 3.20). We then performed confocal microscopy to verify the knockdown of 
EHD2 in the tumors with EHD2 shRNA (Figure 3.21). 
 Following the observation of the dramatic reduction in tumor, we set forth to 
determine the extent of metastasis associated with EHD2 knockdown in TNBC cells. 
Unfortunately, BT549 and HS578t cells are not reliably capable of metastasis. Instead, we 
performed xenograft injections of MDA-MB-231 cells as described above. We found that 
EHD2 knockdown in MDA-MB-231 cells led to a dramatic decrease in final tumor volume 
and a decrease in lung metastasis (Figure 3.22) 
E. Triple-negative breast cancer cells require EHD2 for growth in extracellular 
matrix and plasma membrane repair  
Although a decrease in tumor growth and metastasis was expected in TNBC 
tumors with EHD2 shRNA, the dramatic decrease in tumor volume across all TNBC cell 
lines led us to believe that EHD2 was necessary to an essential function for tumor cells in 
vivo. This lead us to once again investigate bc-GenExMiner to determine what other 
proteins EHD2 was correlated with in breast cancer patient samples and the functions 
those proteins may serve. By investigating gene ontology correlations, we found that 
EHD2 expression was tightly correlated with cellular components associated with the 
extracellular matrix, extracellular region, basement membrane, focal adhesion, and other 
functions associated with the plasma membrane (Table 3.3). This finding led us to next 
examine the growth of EHD2-knockdown TNBC cells within a basement membrane 
extract. To examine this, we used Matrigel, a commercially available mixture of various 
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extracellular matrix components. Matrigel is commonly used to mimic the ECM that 
tumors grow in in vivo (Ortega-Cava et al. 2011; Dimri et al. 2007). We found that EHD2 
knockdown led to dramatic reduction in invasive morphology in MDA-MB-231 (Figure 
3.23 A) and BT549 (Figure 3.24 A) cells grown in Matrigel. The EHD2 knockdown cells 
had fewer invasive projections, often referred to as invadopodia (Hashimoto et al. 2004), 
in both MDA-MB-231 (Figure 3.23 B) and BT549 cells (Figure 3.24 B).  
Given the well-established role of EHD2 in regulating the dynamics of caveolae 
and the more recent discoveries that caveolae play an important role in membrane repair 
and invadopodia formation in cancer (Yamaguchi et al. 2009; H. Yang et al. 2016; Stoeber 
et al. 2012), we sought to determine the effect of EHD2 knockdown on membrane repair 
in TNBC cells. To examine membrane repair, we used a bulk wounding assay with glass 
beads and various cytoplasm staining dyes. Briefly, cells were plated on coverslips and 
then wounded via glass bead rolling. They were then incubated with a CascadeBlue-
conjugated dextran to label cells with damaged membranes. Cells were then allowed to 
reseal their membranes and then incubated with a TRITC-conjugated dextran to label cells 
that failed to repair (Figure 3.25 A). Using this assay, we found that EHD2 knockdown 
resulted in a significantly higher percentage of cells with failed membrane repair in MDA-
MB-231, BT549, and HS578t cells (Figure 3.25 B). These findings suggest that EHD2 
regulation of caveolae is essential to membrane repair processes in TNBC cells.  
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III.2 Tables 
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Table 3.1  
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Table 3.1. Table showing the relationship between EHD2 subgroups and the other 
markers. Of the whole series (840 cases), 759 were informative. The expression of EHD2 
is  detected in the cytoplasm and/or nucleus of the malignant cells while, in the normal 
parenchymal element its expression is noted in the nuclei of epithelial cells only. For 
statistical analysis, expression was dichotomized using cutoff points that were selected 
based on histogram distribution. The cutoff points were selected using median and X-
tile software as follows: an H-score of zero for nuclear EHD2 and H-score of 50 for 
cytoplasmic EHD2 expression.  
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Table 3.2 
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Table 3.2 continued 
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Table 3.2. Association with clinicopathological parameters. Of the whole series (840 
cases), 759 were informative. The expression of EHD2 is  detected in the cytoplasm 
and/or nucleus of the malignant cells while, in the normal parenchymal element its 
expression is noted in the nuclei of epithelial cells only. For statistical analysis, 
expression was dichotomized using cutoff points that were selected based on histogram 
distribution. The cutoff points were selected using median and X-tile software as 
follows: an H-score of zero for nuclear EHD2 and H-score of 50 for cytoplasmic EHD2 
expression. Nuclear and cytoplasmic EHD2 expression showed contrasting associations 
with other variables with loss of nuclear expression and or cytoplasmic expression 
associated with variables characteristic of poor prognosis and shorter survival (tumor 
suppressor gene-like effect). There were associations between loss of nuclear EHD2 
expression and poor prognostic variables including large tumour size, high tumour 
grade with frequent mitoses and high Ki-67, positive vascular invasion and high 
Nottingham Prognostic Index (NPI) scores. Nuclear EHD2 showed positive associations 
with good prognostic biomarkers including hormone receptors (ER, PR, AR) and other 
markers characteristics of the luminal class such as muc1, BEX1, nuclear BRCA1 and 
RAD51, FHIT, FOXA1 and E-cadherin.  Loss of nuclear EHD2 expression was associated 
with basal-like molecular class biomarkers including CK5, CK 17 and Ki-67, and with 
triple negative phenotype and biomarkers associated with EMT including loss of E-
cadherin and expression of N-cadherin. Nuclear EHD2 was associated with AKT and 
PI3K and with ERK (pan-ERK, phospho-ERK and p38). On the other hand, cytoplasmic 
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EHD2 expression showed positive association with poor prognostic markers including 
high grade, high mitotic rate and with basal-like biomarker (CK5) and the apoptosis 
marker Bcl2. 
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Table 3.3 
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Table 3.3. EHD2 association with caveolin-1 status. Cases were defined based on the 
dual expression (CYTO and NUC). Then cases with any nuclear staining were excluded 
(Double CYT and NUC positive as well as the NUC positive CYTO Negative) cases.  
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Table 3.4 
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Table 3.4. EHD2 association with caveolin-2 status. Cases were defined based on the 
dual expression (CYTO and NUC). Then cases with any nuclear staining were excluded 
(Double CYT and NUC positive as well as the NUC positive CYTO Negative) cases.  
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Table 3.5 
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Table 3.5. EHD2 mRNA aassociation with extracellular-mediated cellular processes in 
TNBC patients. Using bc-GenExMiner v 4.0 (Jézéquel et al. 2013; Jézéquel et al. 2012), 
we performed gene correlation exhaustive analysis to identify genes best correlating 
positively to EHD2 in over 700 TNBC patient samples. We then sorted the results into 
their associated Gene Ontology term enrichments. 
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III.3 Figures 
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Figure 3.1 
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Figure 3.1. EHD2 expression in the mammary duct is localized to the myoeptheilium. 
a, Immunoblot analysis of EHD levels in normal murine mammary gland; Hsc70 loading 
control is shown on the bottom panel. b, Immunofluorescence images of normal mouse 
mammary gland. Top row is stained with anti-cytokeratin 8 (CK8) (green) and anti-
EHD2 (red) antibodies. Bottom row is stained with anti-alpha smooth muscle actin 
(SMA) (green) and anti-EHD2 (red). Both rows were counterstained with 4,6-diamidino-
2-phenylindole (DAPI, to stain DNA; blue). Scale bars, 20µm. 
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Figure 3.2 
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Figure 3.2. EHD1 expression in the mammary gland is primarily localized to the 
subcapsular sinus of the mammary lymphnode. a, Immunofluorescence images of 
normal mouse mammary gland stained with anti-EHD1. White arrows indicate 
subscapular sinus region of mammary lymph node. Scale bar: 200 µm. b, 
Immunofluorescence images of normal mouse mammary gland stained with anti-EHD1. 
Scale bar: 100 µm. 
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Figure 3.3 
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Figure 3.3. Confirmation of EHD2 knockout and increased EHD1 expression in the 
mammary gland of EHD2 -/- mice. a, Immunoblot analysis of EHD levels in normal 
murine mammary gland and EHD2 null mammary gland; Hsc70 loading control is 
shown on the bottom panel. b, Immunofluorescence images of 12-week old female 
inguinal mammary glands of EHD2+/+ mice (top row) or EHD2 -/- mice (bottom row) 
stained with anti-EHD2 (left panel) and DAPI (middle panel). Merged images of EHD2 
and DAPI show lack of EHD2 expression in EHD2 -/- mice. (right panel). Scale bars, 200 
µm. b, Immunofluorescence images of 12-week old female inguinal mammary glands of 
EHD2+/+ mice (top row) or EHD2 -/- mice (bottom row) stained with anti-EHD1 (left 
panel) and DAPI (middle panel). Merged images of EHD2 and DAPI show lack of EHD2 
expression in EHD2 -/- mice. (right panel). Scale bars, 100 µm. 
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Figure 3.4 
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Figure 3.4. EHD2 is consistently expressed and localized to the myoepithelial/basal 
layer of the mammary duct. a, Immunohistochemical staining of EHD2 in normal 
human breast tissue sections. Selected area demonstrates the localization of EHD2 
within the human myoepithelial/basal layer. b, Immunohistochemical analysis of EHD2 
in murine mammary gland sections throughout various timepoints of development. 
Images are arranged to show the dynamic cycle of mammary gland development. Scale 
bars, 100 µm.  
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Figure 3.5 
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Figure 3.5. EHD2 and caveolin-1 occupy the same compartments of the mammary 
gland. a, Immunoblot analysis of EHD levels and caveolin-1 levels in normal murine 
mammary gland, EHD2, EHD1, and EHD4 null mammary gland; Hsc70 loading control 
is shown on the bottom panel. b, Immunofluorescence images of 12-week old female 
inguinal mammary glands of mice stained for EHD2 (red, top row) or caveolin-1 (red, 
bottom row), and smooth muscle actin (green), and DAPI (blue). Scale bars, 200 µm.  
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Figure 3.6 
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Figure 3.6. EHD2 and caveolin-1 are primarily expressed in triple-negative breast 
cancer cell lines. a, Immunoblot analysis of EHD levels in non-tumorigenic 
immortalized mammary epithelial cells (76Ntert, MCF10a), luminal A breast cancer cell 
lines (ER+/PR+), luminal B breast cancer cell lines (ER+/PR+, ErbB2+), HER2+ breast 
cancer cell lines (ErbB2+), and Triple-negative breast cancer cell lines (ER-/PR-, ErbB2-); 
Hsc70 loading control is shown on the bottom panel. b, Box-and-whisker plot of EHD2 
mRNA expression levels in Basal A, Basal B, and Luminal cell lines. c, Box-and-whisker 
plot of caveolin-1 mRNA expression levels in Basal A, Basal B, and Luminal cell lines. 
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Figure 3.7 
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Figure 3.7. Cell lines with high EHD2 mRNA expression and high EHD2 and 
caveolin-1 mRNA expression. a, Relative mRNA expression of EHD2 across individual 
basal A, basal B, and luminal cell lines. b,  Relative mRNA expression of EHD2 and 
caveolin-1 across individual Basal A, Basal B, and Luminal cell lines. 
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Figure 3.8 
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Figure 3.8. EHD2 mRNA expression correlates with protein expression in breast 
cancer cell lines. a, EHD2 mRNA is highly expressed primarily within basal-like and 
triple-negative cell lines. b, EHD2 protein is highly expressed within basal-like and 
triple-negative cell lines. c, Immunofluorescence microscopy of EHD2 (red) localizes 
primarily to the plasma membrane of basal-like and triple-negative cell lines. DAPI 
(blue) was used to stain the nucleus. Scale bar indicates 50 µm. d, immunohistochemical 
staining of EHD2 in FFPE sections from xenograft tumors shown at 10x magnification. 
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Figure 3.9 
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Figure 3.9. EHD2 is co-expressed and co-localizes with caveolin-1 in breast cancer 
cells. a, Western blot analysis of multiple breast cancer cell lines shows that EHD2 is 
expressed in triple-negative breast cancer (TNBC) and HER2 positive (HER2+) cells 
expressing caveolin-1. Non-tumorigenic cell lines (76Ntert and 16A5) also express EHD2 
and caveolin-1. b, Immunofluorescence of anti-EHD2 (red) and anti-caveolin-1 (green) in 
TNBC cell lines shows co-localization of both proteins. Scale bar indicates 100 µm. 
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Figure 3.10 
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Figure 3.10. EHD2 mRNA expression positively correlates with caveolin-1 and 
caveolin-2 mRNA expression in human breast cancer. a, Pearson’s pairwise correlation 
heatmap of EHD2, caveolin-1 (CAV1), and caveolin-2 (CAV2) mRNA expression across 
5,277 human breast cancer samples. Red hue indicates strong positive correlation. b, 
Pearson’s pairwise correlation plot of EHD2 and CAV1 mRNA expression for 5,277 
human breast cancer samples. c, Pearson’s pairwise correlation plot of EHD2 and CAV2 
mRNA expression for 5,277 human breast cancer samples. Data obtained from bc-
genExMiner. 
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Figure 3.11 
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Figure 3.11. EHD2 and caveolin mRNA expression is associated with lower 
probability of survival in basal breast cancer. a, Kaplan-Meier survival curve for all 
tumors (left panel) and basal tumors (right panel) for low EHD2 mRNA (black) and high 
EHD2 mRNA (red) b, Kaplan-Meier survival curve for all tumors (left panel) and basal 
tumors (right panel) for low CAV1 mRNA (black) and high CAV1 mRNA (red).  c,   
Kaplan-Meier survival curve for all tumors (left panel) and basal tumors (right panel) for 
low CAV2 mRNA (black) and high CAV2 mRNA (red). All data obtained from 
kmplot.com.  
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Figure 3.12 
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Figure 3.12. Combined EHD2, caveolin-1, and caveolin-2 mRNA expression is 
associated with lower probability of survival in basal breast cancer. a, Kaplan-Meier 
survival curve for distant metastasis-free survival (DMFS) percentage in all tumors for 
low EHD2 mRNA (gray) and high EHD2 mRNA (red) b, Kaplan-Meier survival curve 
for DMFS percentage in basal tumors for low EHD2 mRNA (gray) and high EHD2 
mRNA (red) 
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Figure 3.13 
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Figure 3.13. EHD2 protein expression and localization determines survival probability 
across a cohort of 840 human breast cancer tissue samples. a, Representative images 
(20x magnification) of EHD2 expression levels and nuclear/cytoplasmic localization 
throughout a tumor microarray of 840 human breast cancer samples. 
Immunohistochemistry staining for anti-EHD2 was performed and sent for pathologist 
scoring to Nottingham, U.K. b, Kaplan-Meier survival curve for breast cancer specific 
survival (BCSS) probability in all tumors scored for nuclear positive and cytoplasmic 
negative (green), nuclear positive and cytoplasmic positive (red), nuclear negative and 
cytoplasmic negative (blue), and nuclear negative and cytoplasmic positive (gray) 
expression of EHD2 throughout 840 human breast cancer samples. 
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Figure 3.14 
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Figure 3.14. Cytoplasmic EHD2 expression is associated with TNBC and lower 
probability of survival across a cohort of 840 human breast cancer samples. a, 
Representative images (20x magnification) of negative/low cytoplasmic (left) and 
positive/high cytoplasmic EHD2 expression levels throughout a tumor microarray of 840 
human breast cancer samples. Immunohistochemistry staining for anti-EHD2 was 
performed and sent for pathologist scoring to Nottingham, U.K. b, percentage of 
negative/low (gray) and positive/high cytoplasmic EHD2 samples in luminal, HER2+, 
TN, and all tumors throughout a tumor microarray of 840 human breast cancer samples. 
c, Kaplan-Meier survival curve for Breast Cancer Specific Survival (BCSS) probability in 
all tumors scored for nuclear/low (black) and positive/high cytoplasmic expression of 
EHD2 throughout 840 human breast cancer samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
Figure 3.15 
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Figure 3.15. EHD2 shRNA knockdown reduces invasiveness of TNBC cell lines in 
vitro. a, Western blot analysis of EHD2 expression by MDA-MB-231, BT549, and Hs578t 
cells after retroviral transduction with control or EHD2 shRNA. HSC70 was used as a 
loading control. b, Representative image of transwell invasion extent for TNBC cells 
with control or EHD2 shRNA. Cells were seeded in the top chamber and allowed to 
invade through a Matrigel-coated membrane for 22 hours. c, Quantification of 
invasiveness for TNBC cells with control or EHD2 shRNA after 22 hours. Cells were 
fixed in methanol, stained with HEMA solution, and counted per high power field. * =   
p < 0.05 
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Figure 3.16 
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Figure 3.16. EHD2 shRNA knockdown reduces growth of soft-agar colonies for TNBC 
cell lines. a, Representative image of soft-agar colonies for TNBC cells with control or 
EHD2 shRNA. b, Quantification of the number of soft-agar colonies for TNBC cells with 
control or EHD2 shRNA after two weeks. Cells were fixed in methanol, stained with 
crystal violet, and counted per well. (error bar indicates s.e.m., n=3 experiments, * 
indicates P<0.05, ** indicates P<0.01). 
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Figure 3.17 
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Figure 3.17. EHD2 shRNA knockdown reduces tumorsphere formation in TNBC cell 
lines. a, Representative image of tumorspheres for TNBC cells with control or EHD2 
shRNA. b, Quantification of the number of tumorsphers for TNBC cells with control or 
EHD2 shRNA after one week. Tumorspheres over 40 µm in diameter were counted per 
well. (error bar indicates s.e.m., n=3 experiments, * indicates P<0.05, *** indicates 
P<0.005). 
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Figure 3.18 
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Figure 3.18. EHD2 shRNA-mediated knockdown reduces tumorigenicity of BT549 
cells in vivo. Reduced fold change in tumor volumes in fat pads of athymic mice 
injected with EHD2 shRNA cells compared to control shRNA cells. a, 5x106 BT549 cells 
with control shRNA (filled dots) or EHD2 shRNA (open squares) were injected into 4-
week old aythmic mice, and followed for 13 weeks to estimate fold change in tumor 
volume after injection (each dot or square represents an individual tumor). Each data 
point is the volume of a single tumor (lines indicate median, error bars indicate 
interquartile range). b, Representative images of BT549 xenograft tumors with control 
shRNA (top row) or EHD2 shRNA (bottom row) from athymic mice at the experiment 
endpoint. Tumors shown are representative of the median from each group. 
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Figure 3.19 
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Figure 3.19. EHD2 shRNA-mediated knockdown reduces tumorigenicity of HS578t 
cells in vivo. Reduced fold change in tumor volumes in fat pads of athymic mice 
injected with EHD2 shRNA cells compared to control shRNA cells. a, 5x106 Hs578t cells 
with control shRNA (filled dots) or EHD2 shRNA (open squares) were injected into 4-
week old aythmic mice, and followed for 11 weeks to estimate fold change in tumor 
volume after injection (each dot or square represents an individual tumor). b, 
Representative images of Hs578t xenograft tumors with control shRNA (top row) or 
EHD2 shRNA (bottom row) from athymic mice at the experiment endpoint. Tumors 
shown are representative of the median from each group. 
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Figure 3.20 
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Figure 3.20. EHD2 shRNA-mediated knockdown alters tumor cell morphology and 
reduces proliferation of TNBC cells in vivo. a, Representative images of H&E staining 
of xenograft tumor sections from HS578t cells with control or EHD2 shRNA to 
demonstrate tumor cell morphology. b, Representative images (20x magnification) of 
Ki67 staining of xenograft tumor sections from HS578t cells with control or EHD2 
shRNA. 
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Figure 3.21 
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Figure 3.21. Validation of EHD2 shRNA-mediated knockdown in TNBC cells in vivo. 
a, Representative images of xenograft tumor sections from HS578t cells with control or 
EHD2 shRNA stained with anti-EHD2 (red) and DAPI (blue). Scale bars represent 200 
µm. 
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Figure 3.22 
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Figure 3.22. EHD2-shRNA mediated knockdown reduces metastatic potential of 
TNBC cells in vivo. a, Representative images of primary xenograft tumors and lungs 
from mice injected with 5 x 106 MDA-MB-231 cells with control or EHD2 shRNA. 
Tumors and lungs were harvested 13 weeks after injection of MDA-MB-231 cells. Lung 
metastases were visually counted for each group.  
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Figure 3.23 
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Figure 3.23. EHD2 knockdown reduces invasive growth of MDA-MB-231 cells in 
Matrigel culture. a, MDA-MB-231 cells were plated as single cells in 100% Matrigel and 
allowed to grow for 7 days in culture. Cell invasion through Matrigel was imaged at day 
7. Scale bar represents 1000 µm. Magnified image scale bar represents 200 µm. b, The 
percentage of invasive spheroids per field was quantified for MDA-MB-231 cells with 
control or EHD2 shRNA (Each dot represents a field, *** indicates p<0.001).  
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Figure 3.24 
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Figure 3.24. EHD2 knockdown reduces invasive growth of BT549 cells in Matrigel 
culture. a, BT549 cells were plated as single cells in 100% Matrigel and allowed to grow 
for 7 days in culture. Cell invasion through Matrigel was imaged at day 7. Scale bar 
represents 1000 µm. Magnified image scale bar represents 200 µm. b, The percentage of 
invasive spheroids per field was quantified for BT549 cells with control or EHD2 shRNA 
(Each dot represents a field, *** indicates p<0.001). 
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Figure 3.25 
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Figure 3.25. EHD2 knockdown reduces TNBC cell membrane repair ability in vitro. a,  
TNBC cells with control or EHD2 shRNA were incubated with CascadeBlue-conjugated 
dextran to label cells with damaged membranes via bulk membrane wounding from 
glass bead rolling. Five minutes after wounding, cells were rinsed and incubated with 
TRITC-conjugated dextran to label cells that failed to repair. Hs578t cells are shown as 
representative for the effects of EHD2 knockdown on membrane repair. Scale bar 
represents 200 µm. b, The number of wounded cells with repaired membranes were 
compared to the number cells with failed membrane repair and represented as a 
percentage for MDA-MB-231, BT549, and Hs578t cells. Quantification represents three 
independent experiments. P<0.001 (***), p<0.0001 (****) 
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III.4 Discussion 
 In this chapter, we have shown that EHD2 is a novel marker and important 
regulator of membrane repair and tumorigenicity in triple-negative breast cancer. We 
first demonstrated that EHD2 is exclusively expressed within the myoepithelial/basal 
layer of the murine and human mammary duct. We used a newly developed EHD2-/- 
mouse strain to validate our EHD2 antibody specificity and confirmed the exclusive 
expression of EHD2 throughout the major timepoints of mammary gland development. 
In accordance with its role as an essential regulator of caveolae dynamics, EHD2 
localization in the mammary duct was consistent with the known expression pattern of 
the caveolae structural proteins, caveolin-1 and caveolin-2 (Pinilla et al. 2006; Savage et 
al. 2008). While EHD2 knockout in mice did not result in an obvious phenotype, we did 
observe a distinct increase of EHD1 expression within the myoepithelial/basal layer of 
the mammary duct. This suggests that EHD1 may serve a functionally redundant role to 
EHD2 within these compartments. Interestingly, other tissues of EHD2-/- mice did not 
exhibit similar increases in EHD1 expression (data not shown), and shRNA-mediated 
knockdown of EHD2 in mammary epithelial cells and breast cancer cells did not elicit 
increased EHD1 protein expression. This suggests that the observed increase of EHD1 in 
EHD2-/- mice may be regulated via genomic mechanisms instead of through protein 
expression levels. More research into this phenomenon would be interesting since the 
members of the EHD family of proteins have many overlapping cellular functions 
(George et al. 2007; Cai et al. 2013).  Regardless, this compartment-specific redundancy 
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role of EHDs has been observed previously in other EHD knockout mice (Sengupta et al. 
2009; George et al. 2011).   
 Our findings in normal mammary gland tissue were paralleled by the expression 
of EHD2 in breast cancer cell line subtypes. Most triple-negative breast cancers are often 
referred to as basal-like breast cancer because they have a gene expression profile similar 
to the myoepithelial/basal layer of the mammary duct (Savage et al. 2007; Charafe-
Jauffret et al. 2006; Jacquemier et al. 2005; Neve et al. 2006; Chin et al. 2006). Our 
initialing screening of 24 breast cancer cell lines demonstrated that EHD2 protein 
expression levels were indeed present in basal-like cells and mostly absent in luminal 
and HER2-positive breast cancer lines. These results were further validated by using a 
publicly available breast cancer cell line expression database (Ringnér et al. 2011) based 
on gene expression data and molecular subtype classifications that were previously 
described (Neve et al. 2006). Moreover, EHD2 mRNA expression was positively 
correlated with both caveolin-1 and caveolin-2 mRNA, and was primarily expressed 
within the highly-metastatic basal B molecular subtype.  
To expand our use of the publicly-available breast cancer gene expression 
databases, we showed that EHD2 mRNA expression correlated with EHD2 protein 
expression in a select set of breast cancer cell lines both in vitro and in vivo. Importantly, 
we also presented the novel finding that EHD2 and caveolin-1 protein expression was 
co-expressed and co-localized nearly perfect throughout our selected breast cancer cell 
lines. The co-localization of caveolin-1 and EHD2 in TNBC cell lines was predominantly 
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in the rear of motile cells in vitro. While the caveolin-1 localization was consistent with 
what has been shown for other cell systems (Masuelli et al. 2012; H. Yang et al. 2016), 
there was a fraction of EHD2 that was localized near the cell front and not co-localized 
with caveolin-1. This suggests that EHD2 is serving a role at the leading edge of motile 
TNBC cells that is independent of any regulatory roles involving caveolae. However, 
this could also be a misinterpretation since caveolae can also exist in a flattened state 
(Nassoy and Lamaze 2012; Senju and Suetsugu 2016) and the rear of the cell may simply 
represent a more concentrated pool of caveolae.  This question could be answered in the 
future with additional imaging experiments using electron microscopy (Sinha et al. 
2011).  
 Our findings also demonstrated that EHD2 mRNA was positively correlated 
with caveolin-1 and caveolin-2 mRNA expression in human breast cancer samples. 
While EHD2 mRNA expression was not associated with any significant difference in 
survival probability across all breast tumor subtypes, we did find that high EHD2 
mRNA expression was significantly associated with lower survival probability in 
patients with basal tumors. Caveolin-1 and caveolin-2 mRNA expression analysis 
yielded similar results, once again confirming the close association between EHD2 and 
the structural proteins of caveolae in TNBC. It is important to note that we also observe 
high EHD2 expression within the stromal compartment of the mammary gland, mainly 
adipocytes and endothelial cells. This could skew EHD2 mRNA expression levels if the 
samples weren’t dissected carefully or analyzed via a process such as laser capture 
microdissection (Braakman et al. 2017). However, given the similar survival probability 
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profiles of caveolin-1 and caveolin-2 and the fact that they are expressed in the same 
stromal compartments as EHD2, we can assume that the results from the mRNA 
expression database are an accurate representation of tumor expression. This is 
supported by research indicating that low stromal caveolin-1 expression is associated 
with a lower probability of survival in breast cancer (Qian et al. 2011; Goetz et al. 2011). 
Therefore, we can presume that any lower probability of survival from high caveolin-1 
mRNA expression stems from tumor expression rather than stromal expression. 
We followed up our findings from the mRNA expression database by validating 
EHD2 protein expression in TNBC in a well-annotated TMA of 840 breast cancer 
samples. Interestingly, we found that EHD2 protein localization within tumor samples 
influence survival probability and varied by subtype. Although cytoplasmic EHD2 
expression was consistent with our mRNA data and associated with TNBC and lower 
probability of survival, EHD2 expression in the nucleus was associated with luminal 
subtypes of breast cancer and a higher probability of survival. This nuclear expression of 
EHD2 could explain the discrepancies we observed regarding EHD2 mRNA expression 
and survival probability. Specifically, nuclear expression of EHD2 could be the reason 
why high EHD2 mRNA expression does not show a significant difference in survival 
across all breast tumor subtypes. It is also possible that our observations of nuclear 
EHD2 are simply an artifact of sample preparation through immunohistochemistry. 
Future experiments to isolate cytoplasmic and nuclear fractions of breast cancer cells 
could help validate our IHC findings. Still, EHD2 does have a nuclear localization 
sequence and has been shown to traffic to the nucleus (Pekar et al. 2012; Bahl, 
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Naslavsky, and Caplan 2015). While the function of EHD2 shuttling to the nucleus is 
mostly unclear, our observations are the first time that differential nuclear and 
cytoplasmic expression of EHD2 has been documented in cancer.   
 Disregarding nuclear expression, however, our TMA results did indicate a 
significant association between cytoplasmic EHD2 and caveolin-2 expression.  Although 
caveolin-1 did not exhibit the same significant association, caveolin-1 and caveolin-2 
were shown to be associated with TNBC in the same cohort of patient samples (Elsheikh 
et al. 2008). The expression of EHD2, caveolin-1/2, and other basal-like markers in TNBC 
could be a due to the cancer originating from the myoepithelial/basal layer or simply 
part of a transcriptomic program that leads to a basal-like phenotype (Savage et al. 
2008). Regardless, these findings demonstrate that EHD2 is a novel marker of TNBC and 
an indicator of poor outcome, and may be serving an important regulatory role for 
caveolae in TNBC. 
 Metastasis is the ultimate cause of death among the overwhelming majority of 
breast cancer patients (Kast et al. 2015; Gerratana et al. 2015; Wu et al. 2016). Triple-
negative breast cancer comprises only 10%- 15% of all breast cancer cases, yet it is 
clinically challenging due to its highly metastatic nature (Marmé and Schneeweiss 2015; 
Molnár et al. 2017). To expand upon our observational findings, we selected three cell 
lines (MDA-MB-231, BT549, and HS578T) to test the functional effects of EHD2 shRNA-
mediated knockdown in TNBC. Our initial findings demonstrated that EHD2 
knockdown resulted in decreased invasiveness and tumorigenicity of TNBC both in vitro 
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and in vivo. EHD2 knockdown did not significantly affect proliferation, migration, or 
morphology of TNBC cells in normal 2D culture conditions. However, we found that 
EHD2 knockdown significantly reduced invasiveness and anchorage-independent 
growth in vitro. These results conform with our observational findings but also suggest 
that EHD2 could be regulating the tumorigenicity or viability of the cancer stem cell 
population in TNBC. Interestingly, previous studies of EHD2 in breast cancer described 
the opposite effect (X. Yang et al. 2015; Yuhua Shi et al. 2015). Briefly, EHD2 was 
suggested to serve as a tumor suppressor since siRNA-mediated knockdown led to 
enhanced migration and invasion in MDA-MB-231 and MCF7 cells. Our findings 
suggest the contrary. Not only did our study utilize a well-annotated and 10-fold larger 
cohort of breast cancer patient samples, but we also confirmed that the MCF7 cell line 
lacks EHD2 expression through western blotting, immunofluorescence, and multiple 
publicly available mRNA expression databases. Furthermore, we demonstrated that 
EHD2 knockdown dramatically reduces tumor growth and metastasis in vivo using 
MDA-MB-231, BT549, and HS578T orthotopic tumors. We also validated the specificity 
of our EHD2-antibody through western blot and immunofluorescence analysis of cells 
with EHD2 shRNA and tissue from EHD2-/- mice. These findings suggest that EHD2 
plays a novel role as an indispensable regulator of tumorigenicity and metastatic 
potential in TNBC. 
 In breast cancer, breast density and matrix-stiffness are associated with poorer 
outcome (Wei et al. 2015; Provenzano et al. 2009). Breast cancer cells rely on mechano-
protective and membrane repair processes to maintain their high growth rate and to 
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survive in hostile tumor microenvironments. Furthermore, caveolin-1, a required 
structural component of caveolae, has recently been shown to be upregulated in TNBC 
cells subjected to fluid shear stress, indicating that caveolae serve a mechanoprotective 
role during breast cancer metastasis (H. Yang et al. 2016). Previous studies have 
confirmed that EHD2-interacting proteins such as myoferlin localize to caveolae and 
regulate membrane repair in TNBC and lung carcinomas (Turtoi et al. 2013; Leung et al. 
2013). While caveolae and EHD2 have established roles in membrane repair (Doherty et 
al. 2008; Marg et al. 2012; Schilling and Patel 2015; Yin Shi et al. 2015; Echarri and Del 
Pozo 2015), little is known about the role of EHD2 in regulating caveolae-mediated 
membrane repair. Although our orthotopic tumor model results showed that EHD2 
knockdown decreased tumor growth, the tumors with EHD2 shRNA were still able to 
grow to an extent. We found that the tumors with EHD2 shRNA grew at rate similar to 
control shRNA tumors up to four weeks after implantation. After week four, the EHD2 
shRNA tumors halted growth and maintained their volume until the end of the 
experiment (11 – 13 weeks), indicating that the tumors were unable to maintain a larger 
burden. Although we observed decreased proliferation in EHD2 shRNA tumors, we also 
saw a dramatic loss of the stellate tumor cell morphology characteristic of MDA-MB-231, 
BT549, and HS578T cell lines (Hughes et al. 2008; Nguyen-Ngoc et al. 2015). This 
observation was repeated in vitro by 3D-culturing of TNBCs in Matrigel, indicating a 
defect in the membrane protective processes required for TNBC invadopodia. Further 
analysis confirmed that EHD2 regulates membrane repair in TNBC, consistent with its 
established role in controlling caveolar dynamics and membrane repair in other models. 
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Altogether, these findings suggest that EHD2 is serving a novel role as an essential 
regulator of caveolar-mediated membrane-protective functions in TNBC.  
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Chapter IV: Conclusions and Future 
Directions 
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IV.1 Conclusions  
In summary, we used publicly available gene expression databases, clinical 
breast cancer samples, and shRNA-mediated knockdown within in vitro and in vivo 
breast cancer models to provide evidence that EHD2, a member of the EHD protein 
family of endocytic recycling regulators, serves a novel and critical role in regulating 
caveolar-mediated mechanisms of plasma membrane maintenance essential for tumor 
growth and development in Triple-negative breast cancer.  
Based on our studies, EHD2 is fundamentally important for triple-negative 
breast cancer invasiveness and tumor growth. Moreover, EHD2 is a key regulator of 
caveolae dynamics and interacts with proteins that regulate the caveolae-mediated 
membrane repair and protection processes. These mechanoprotective functions of 
caveolae allow TNBC cells to maintain their high growth rate, survive in the hostile 
tumor microevironment, and metastasize. Given our observations that EHD2 is highly 
expressed and critical for tumorigenesis in TNBC, as well as previous studies that have 
solved the structure of EHD2 and found it to be an important regulator of caveolae 
dynamics and stability through ATP binding, our findings here have uncovered a novel 
function of EHD2 as regulator of caveolae-mediated mechanoprotection in cancer that 
may be a potential therapy target for TNBC via specific inhibition of EHD2 ATPase 
activity. Further exploration of other human cancers may show a broader role of EHD2 
across human cancer pathogenesis. 
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IV.2 Future Directions 
 In this thesis, we demonstrated the co-expression of and co-localization of EHD2 
and caveolin-1 in triple-negative breast cancer. We also showed that EHD2 was 
indispensable for plasma membrane repair and invasive spheroid formation in TNBC 
cell lines. While this is consistent with the role of caveolae in membrane repair and role 
of EHD2 in regulating caveolae, we still need to confirm that EHD2 is directly 
influencing caveolar-mediated membrane repair processes. To accomplish task, future 
studies will need to perform structure function analysis to determine which domains of 
EHD2 are required for efficient plasma membrane repair. Transfection of EHD2 mutant 
constructs into TNBC cells to recapitulate the membrane repair phenotype will help 
establish which domains are essential for this process. While many EHD2 mutants have 
been generated and discussed in the literature, the EHD2 mutant unable to bind ATP 
(EHD2 T72A) has been shown to be unable to interact and regulate caveolae (Moren et 
al. 2012; Stoeber et al. 2012). However, it would also be prudent to instigate the many 
EHD2 interacting partners (myoferlin, pacsin 2, cavin 1, and cavin 2) that are also known 
to be associated and/or important for caveolae formation and regulation. Additional 
shRNA-mediated knockdown of caveolin-1 and caveolin-1 in TNBC cells would aslo 
help confirm our hypothesis if knockdown is able to recapitulate our observed 
phenotypes of defective membrane repair and reduced tumorigenicity.  
 Despite the clear association of EHD2 with triple-negative breast cancer, most 
breast cancer samples and cell lines do not express EHD2. This is an interesting finding 
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that needs to be examined further. Moreover, previous studies have shown that 
membrane repair is essential to the invasiveness of these breast cancer cells lacking 
EHD2, specifically the luminal subtype cell lines MCF7 (Jaiswal et al. 2014). The MCF7 
cells were found to rely mostly on annexin and s100 protein mediated repair pathways, 
indicating that caveolae-independent repair mechanisms are present in these cells, but it 
would be crucial to investigate other luminal A, luminal B, and HER2+ cell lines. While 
we show that caveolin-1 is primarily expressed in TNBC, some TNBC cell lines like 
MDA-MB-468 do not express the protein or EHD2. These cells would also be important 
to investigate. Moreover, although EHD2 is absent, we have shown that EHD1 and 
EHD4 are highly expressed in luminal and most HER2+ cell lines. It would be prudent 
to investigate the role of these EHDs in regard to plasma membrane repair. 
Additionally, our lab has demonstrated that EHD1 is a critical component in the 
trafficking and signaling of the receptor tyrosine kinase CSF1-R in macrophages (Cypher 
et al. 2016). Given that HER2 is a receptor tyrosine kinase, it would interesting to 
examine the effects of EHD1 shRNA-mediate knockdown within these cells. The same 
experiments would be worthy of investigating within the EHD2-absent, TNBC cell lines 
that are high in EGFR expression. 
 Finally, if the ATP-binding deficient mutant, EHD2 T72A, is able to recapitulate 
the plasma membrane repair defects observed in TNBC cells with EHD2 knockdown, 
development of an ATP-binding pocket specific inhibitor could provide enormous 
therapeutic potential to TNBC patients in the future.  
130 
 
 
 
 
 
 
 
Bibliography 
 
 
  
131 
 
Aoki, M N, M K Amarante, J M M Oda, and M A E Watanabe. 2011. “Caveolin 
Involvement and Modulation in Breast Cancer.” Mini Reviews in Medicinal Chemistry 
11 (13): 1143–52. http://www.ncbi.nlm.nih.gov/pubmed/22353223. 
Bahl, Kriti, Naava Naslavsky, and Steve Caplan. 2015. “Role of the EHD2 Unstructured 
Loop in Dimerization, Protein Binding and Subcellular Localization.” Edited by 
Ruben Claudio Aguilar. PLOS ONE 10 (4): e0123710. 
doi:10.1371/journal.pone.0123710. 
Bailey, Tameka A, Haitao Luan, Eric Tom, Timothy Alan Bielecki, Bhopal Mohapatra, 
Gulzar Ahmad, Manju George, et al. 2014. “A Kinase Inhibitor Screen Reveals 
Protein Kinase C-Dependent Endocytic Recycling of ErbB2 in Breast Cancer Cells.” 
The Journal of Biological Chemistry 289 (44): 30443–58. doi:10.1074/jbc.M114.608992. 
Bernatchez, Pascal N, Arpeeta Sharma, Pinar Kodaman, and William C Sessa. 2009. 
“Myoferlin Is Critical for Endocytosis in Endothelial Cells.” American Journal of 
Physiology. Cell Physiology 297 (3): C484-92. doi:10.1152/ajpcell.00498.2008. 
Blouin, Cédric M, Cécilia Prado, Karen K Takane, Françoise Lasnier, Adolfo Garcia-
Ocana, Pascal Ferré, Isabelle Dugail, and Eric Hajduch. 2010. “Plasma Membrane 
Subdomain Compartmentalization Contributes to Distinct Mechanisms of 
Ceramide Action on Insulin Signaling.” Diabetes 59 (3): 600–610. doi:10.2337/db09-
0897. 
Braakman, René B. H., Christoph Stingl, Madeleine M. A. Tilanus-Linthorst, Carolien H. 
M. van Deurzen, Mieke A. M. Timmermans, Marcel Smid, John A. Foekens, Theo 
M. Luider, John W. M. Martens, and Arzu Umar. 2017. “Proteomic Characterization 
of Microdissected Breast Tissue Environment Provides a Protein-Level Overview of 
Malignant Transformation.” PROTEOMICS 17 (5): 1600213. 
doi:10.1002/pmic.201600213. 
Briand, Nolwenn, Cécilia Prado, Guillaume Mabilleau, Françoise Lasnier, Xavier Le 
Lièpvre, Jeffrey D Covington, Eric Ravussin, Soazig Le Lay, and Isabelle Dugail. 
2014. “Caveolin-1 Expression and Cavin Stability Regulate Caveolae Dynamics in 
Adipocyte Lipid Store Fluctuation.” Diabetes 63 (12): 4032–44. doi:10.2337/db13-
1961. 
Cai, Bishuang, Sai Srinivas Panapakkam Giridharan, Jing Zhang, Sugandha Saxena, Kriti 
Bahl, John a Schmidt, Paul L Sorgen, Wei Guo, Naava Naslavsky, and Steve 
Caplan. 2013. “Differential Roles of C-Terminal Eps15 Homology Domain Proteins 
as Vesiculators and Tubulators of Recycling Endosomes.” The Journal of Biological 
Chemistry 288 (42): 30172–80. doi:10.1074/jbc.M113.488627. 
Charafe-Jauffret, E, C Ginestier, F Monville, and P Finetti. 2006. “Gene Expression 
Profiling of Breast Cell Lines Identifies Potential New Basal Markers.” Oncogene. 
http://www.nature.com/onc/journal/v25/n15/abs/1209254a.html. 
132 
 
Cheng, Jade P X, Carolina Mendoza-Topaz, Gillian Howard, Jessica Chadwick, Elena 
Shvets, Andrew S Cowburn, Benjamin J Dunmore, Alexi Crosby, Nicholas W 
Morrell, and Benjamin J Nichols. 2015. “Caveolae Protect Endothelial Cells from 
Membrane Rupture during Increased Cardiac Output.” The Journal of Cell Biology 
211 (1): 53–61. doi:10.1083/jcb.201504042. 
Chin, Koei, Sandy DeVries, Jane Fridlyand, Paul T. Spellman, Ritu Roydasgupta, Wen-
Lin Kuo, Anna Lapuk, et al. 2006. “Genomic and Transcriptional Aberrations 
Linked to Breast Cancer Pathophysiologies.” Cancer Cell 10 (6): 529–41. 
doi:10.1016/j.ccr.2006.10.009. 
Cipta, Stephanie, and Hemal H Patel. 2009. “Molecular Bandages: Inside-Out, Outside-in 
Repair of Cellular Membranes. Focus on ‘Myoferlin Is Critical for Endocytosis in 
Endothelial Cells’.” American Journal of Physiology. Cell Physiology 297 (3): C481-3. 
doi:10.1152/ajpcell.00288.2009. 
Corrotte, Matthias, Patricia E Almeida, Christina Tam, Thiago Castro-Gomes, Maria 
Cecilia Fernandes, Bryan A Millis, Mauro Cortez, et al. 2013. “Caveolae 
Internalization Repairs Wounded Cells and Muscle Fibers.” eLife 2 (January): 
e00926. doi:10.7554/eLife.00926. 
Cypher, Luke R, Timothy Alan Bielecki, Lu Huang, Wei An, Fany Iseka, Eric Tom, 
Matthew D Storck, Adam D Hoppe, Vimla Band, and Hamid Band. 2016. “CSF-1 
Receptor Signalling Is Governed by Pre-Requisite EHD1 Mediated Receptor 
Display on the Macrophage Cell Surface.” Cellular Signalling 28 (9): 1325–35. 
doi:10.1016/j.cellsig.2016.05.013. 
Daumke, Oliver, Richard Lundmark, Yvonne Vallis, Sascha Martens, P Jonathan G 
Butler, and Harvey T McMahon. 2007. “Architectural and Mechanistic Insights into 
an EHD ATPase Involved in Membrane Remodelling.” Nature 449 (7164): 923–27. 
doi:10.1038/nature06173. 
Defour, Aurelia, S C Sreetama, and Jyoti K Jaiswal. 2014. “Imaging Cell Membrane 
Injury and Subcellular Processes Involved in Repair.” Journal of Visualized 
Experiments : JoVE, no. 85(January). doi:10.3791/51106. 
Demonbreun, Alexis R., Mattia Quattrocelli, David Y. Barefield, Madison V. Allen, 
Kaitlin E. Swanson, and Elizabeth M. McNally. 2016. “An Actin-Dependent 
Annexin Complex Mediates Plasma Membrane Repair in Muscle.” The Journal of 
Cell Biology 213 (6): 705–18. doi:10.1083/jcb.201512022. 
Dimri, Manjari, Mayumi Naramura, Lei Duan, Jing Chen, Cesar Ortega-Cava, 
Gengsheng Chen, Rasna Goswami, et al. 2007. “Modeling Breast Cancer-Associated 
c-Src and EGFR Overexpression in Human MECs: C-Src and EGFR Cooperatively 
Promote Aberrant Three-Dimensional Acinar Structure and Invasive Behavior.” 
Cancer Research 67 (9): 4164–72. doi:10.1158/0008-5472.CAN-06-2580. 
133 
 
Doherty, Katherine R, Alexis R Demonbreun, Gregory Q Wallace, Andrew Cave, Avery 
D Posey, Konstantina Heretis, Peter Pytel, and Elizabeth M McNally. 2008. “The 
Endocytic Recycling Protein EHD2 Interacts with Myoferlin to Regulate Myoblast 
Fusion.” The Journal of Biological Chemistry 283 (29): 20252–60. 
doi:10.1074/jbc.M802306200. 
Echarri, Asier, and Miguel A Del Pozo. 2015. “Caveolae - Mechanosensitive Membrane 
Invaginations Linked to Actin Filaments.” Journal of Cell Science 128 (15): 2747–58. 
doi:10.1242/jcs.153940. 
Elsheikh, S E, A R Green, E A Rakha, R M Samaka, A A Ammar, D Powe, J S Reis-Filho, 
and I O Ellis. 2008. “Caveolin 1 and Caveolin 2 Are Associated with Breast Cancer 
Basal-like and Triple-Negative Immunophenotype.” British Journal of Cancer 99 (2): 
327–34. doi:10.1038/sj.bjc.6604463. 
Engelman, J A, R J Lee, A Karnezis, D J Bearss, M Webster, P Siegel, W J Muller, J J 
Windle, R G Pestell, and M P Lisanti. 1998. “Reciprocal Regulation of Neu Tyrosine 
Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo. 
Implications for Human Breast Cancer.” The Journal of Biological Chemistry 273 (32): 
20448–55. http://www.ncbi.nlm.nih.gov/pubmed/9685399. 
Feldman, Rebecca, Zoran Gatalica, Sandeep K. Reddy, Michael Castro, and Jasgit C. 
Sachdev. 2015. “Caveolin-1: Oncogenic Role in Breast Cancer? Clues from 
Molecular Profiling.” ASCO Meeting Abstracts 33 (28_suppl): 134. 
http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/28_suppl/134. 
Fellmann, Christof, Thomas Hoffmann, Vaishali Sridhar, Barbara Hopfgartner, Matthias 
Muhar, Mareike Roth, Dan Yu Lai, et al. 2013. “An Optimized microRNA Backbone 
for Effective Single-Copy RNAi.” Cell Reports 5 (6): 1704–13. 
doi:10.1016/j.celrep.2013.11.020. 
George, Manju, Mark A Rainey, Mayumi Naramura, Kirk W Foster, Melissa S Holzapfel, 
Laura L Willoughby, GuoGuang Ying, et al. 2011. “Renal Thrombotic 
Microangiopathy in Mice with Combined Deletion of Endocytic Recycling 
Regulators EHD3 and EHD4.” PloS One 6 (3). Public Library of Science: e17838. 
doi:10.1371/journal.pone.0017838. 
George, Manju, GuoGuang Ying, Mark A Rainey, Aharon Solomon, Pankit T Parikh, 
Qingshen Gao, Vimla Band, and Hamid Band. 2007. “Shared as Well as Distinct 
Roles of EHD Proteins Revealed by Biochemical and Functional Comparisons in 
Mammalian Cells and C. Elegans.” BMC Cell Biology 8 (January): 3. 
doi:10.1186/1471-2121-8-3. 
Gerratana, L., V. Fanotto, M. Bonotto, S. Bolzonello, A. M. Minisini, G. Fasola, and F. 
Puglisi. 2015. “Pattern of Metastasis and Outcome in Patients with Breast Cancer.” 
Clinical & Experimental Metastasis 32 (2): 125–33. doi:10.1007/s10585-015-9697-2. 
134 
 
Goetz, Jacky G, Susana Minguet, Inmaculada Navarro-Lérida, Juan José Lazcano, Rafael 
Samaniego, Enrique Calvo, Marta Tello, et al. 2011. “Biomechanical Remodeling of 
the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and 
Metastasis.” Cell 146 (1). Elsevier: 148–63. doi:10.1016/j.cell.2011.05.040. 
Gudmundsson, Hjalti, Thomas J Hund, Patrick J Wright, Crystal F Kline, Jedidiah S 
Snyder, Lan Qian, Olha M Koval, et al. 2010. “EH Domain Proteins Regulate 
Cardiac Membrane Protein Targeting.” Circulation Research 107 (1): 84–95. 
doi:10.1161/CIRCRESAHA.110.216713. 
Györffy, Balazs, Andras Lanczky, Aron C Eklund, Carsten Denkert, Jan Budczies, 
Qiyuan Li, and Zoltan Szallasi. 2010. “An Online Survival Analysis Tool to Rapidly 
Assess the Effect of 22,277 Genes on Breast Cancer Prognosis Using Microarray 
Data of 1,809 Patients.” Breast Cancer Research and Treatment 123 (3): 725–31. 
doi:10.1007/s10549-009-0674-9. 
Hansen, Carsten Gram, Gillian Howard, and Benjamin J Nichols. 2011. “Pacsin 2 Is 
Recruited to Caveolae and Functions in Caveolar Biogenesis.” Journal of Cell Science 
124 (Pt 16): 2777–85. doi:10.1242/jcs.084319. 
Hashimoto, Shigeru, Yasuhito Onodera, Ari Hashimoto, Miwa Tanaka, Michinari 
Hamaguchi, Atsuko Yamada, and Hisataka Sabe. 2004. “Requirement for Arf6 in 
Breast Cancer Invasive Activities.” Proceedings of the National Academy of Sciences of 
the United States of America 101 (17): 6647–52. doi:10.1073/pnas.0401753101. 
Hughes, Linda, Catherine Malone, Saranya Chumsri, Angelika M Burger, and Susan 
McDonnell. 2008. “Characterisation of Breast Cancer Cell Lines and Establishment 
of a Novel Isogenic Subclone to Study Migration, Invasion and Tumourigenicity.” 
Clinical & Experimental Metastasis 25 (5): 549–57. doi:10.1007/s10585-008-9169-z. 
Inman, J. L., C. Robertson, J. D. Mott, and M. J. Bissell. 2015. “Mammary Gland 
Development: Cell Fate Specification, Stem Cells and the Microenvironment.” 
Development 142 (6): 1028–42. doi:10.1242/dev.087643. 
Jacquemier, Jocelyne, Laetitia Padovani, Laetitia Rabayrol, Sunil R Lakhani, Frédérique 
Penault-Llorca, Yves Denoux, Maryse Fiche, et al. 2005. “Typical Medullary Breast 
Carcinomas Have a Basal/myoepithelial Phenotype.” The Journal of Pathology 207 
(3): 260–68. doi:10.1002/path.1845. 
Jézéquel, Pascal, Mario Campone, Wilfried Gouraud, Catherine Guérin-Charbonnel, 
Christophe Leux, Gabriel Ricolleau, and Loïc Campion. 2012. “Bc-GenExMiner: An 
Easy-to-Use Online Platform for Gene Prognostic Analyses in Breast Cancer.” Breast 
Cancer Research and Treatment 131 (3): 765–75. doi:10.1007/s10549-011-1457-7. 
Jézéquel, Pascal, Jean-Sébastien Frénel, Loïc Campion, Catherine Guérin-Charbonnel, 
Wilfried Gouraud, Gabriel Ricolleau, and Mario Campone. 2013. “Bc-GenExMiner 
3.0: New Mining Module Computes Breast Cancer Gene Expression Correlation 
135 
 
Analyses.” Database : The Journal of Biological Databases and Curation 2013 (0): bas060. 
doi:10.1093/database/bas060. 
Kast, Karin, Theresa Link, Katrin Friedrich, Andrea Petzold, Antje Niedostatek, Olaf 
Schoffer, Carmen Werner, et al. 2015. “Impact of Breast Cancer Subtypes and 
Patterns of Metastasis on Outcome.” Breast Cancer Research and Treatment 150 (3): 
621–29. doi:10.1007/s10549-015-3341-3. 
Lehmann, Brian D, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, 
Yu Shyr, and Jennifer A Pietenpol. 2011. “Identification of Human Triple-Negative 
Breast Cancer Subtypes and Preclinical Models for Selection of Targeted 
Therapies.” The Journal of Clinical Investigation 121 (7): 2750–67. 
doi:10.1172/JCI45014. 
Leung, Cleo, Carol Yu, Michelle I. Lin, Cristina Tognon, and Pascal Bernatchez. 2013. 
“Expression of Myoferlin in Human and Murine Carcinoma Tumors: Role in 
Membrane Repair, Cell Proliferation, and Tumorigenesis.” American Journal of 
Pathology 182 (5): 1900–1909. doi:10.1016/j.ajpath.2013.01.041. 
Lo, Harriet P, Susan J Nixon, Thomas E Hall, Belinda S Cowling, Charles Ferguson, 
Garry P Morgan, Nicole L Schieber, et al. 2015. “The Caveolin-Cavin System Plays a 
Conserved and Critical Role in Mechanoprotection of Skeletal Muscle.” The Journal 
of Cell Biology 210 (5): 833–49. doi:10.1083/jcb.201501046. 
Ludwig, Alexander, Gillian Howard, Carolina Mendoza-Topaz, Thomas Deerinck, 
Mason Mackey, Sara Sandin, Mark H Ellisman, and Benjamin J Nichols. 2013. 
“Molecular Composition and Ultrastructure of the Caveolar Coat Complex.” PLoS 
Biology 11 (8): e1001640. doi:10.1371/journal.pbio.1001640. 
Malhotra, Gautam K, Xiangshan Zhao, Hamid Band, and Vimla Band. 2010. 
“Histological, Molecular and Functional Subtypes of Breast Cancers.” Cancer 
Biology & Therapy 10 (10): 955–60. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3047091&tool=pmcentr
ez&rendertype=abstract. 
Marg, Andreas, Verena Schoewel, Tobias Timmel, Anne Schulze, Claudio Shah, Oliver 
Daumke, and Simone Spuler. 2012. “Sarcolemmal Repair Is a Slow Process and 
Includes EHD2.” Traffic (Copenhagen, Denmark) 13 (9): 1286–94. doi:10.1111/j.1600-
0854.2012.01386.x. 
Marmé, Frederik, and Andreas Schneeweiss. 2015. “Targeted Therapies in Triple-
Negative Breast Cancer.” Breast Care (Basel, Switzerland) 10 (3): 159–66. 
doi:10.1159/000433622. 
Martinez-Outschoorn, Ubaldo E, Federica Sotgia, and Michael P Lisanti. 2015. “Caveolae 
and Signalling in Cancer.” Nature Reviews. Cancer 15 (4). Nature Publishing Group, 
a division of Macmillan Publishers Limited. All Rights Reserved.: 225–37. 
136 
 
doi:10.1038/nrc3915. 
Masuelli, Laura, Alfredo Budillon, Laura Marzocchella, Marie-Agnes Mrozek, Domenico 
Vitolo, Elena Di Gennaro, Simona Losito, et al. 2012. “Caveolin-1 Overexpression Is 
Associated with Simultaneous Abnormal Expression of the E-Cadherin/α-β 
Catenins Complex and Multiple ErbB Receptors and with Lymph Nodes Metastasis 
in Head and Neck Squamous Cell Carcinomas.” Journal of Cellular Physiology 227 
(9): 3344–53. doi:10.1002/jcp.24034. 
Mercier, Isabelle, Mathew C Casimiro, Jie Zhou, Chenguang Wang, Christopher 
Plymire, Kelly G Bryant, Kristin M Daumer, et al. 2009. “Genetic Ablation of 
Caveolin-1 Drives Estrogen-Hypersensitivity and the Development of DCIS-like 
Mammary Lesions.” The American Journal of Pathology 174 (4): 1172–90. 
doi:10.2353/ajpath.2009.080882. 
Mercier, Isabelle, and Michael P Lisanti. 2012. “Caveolin-1 and Breast Cancer: A New 
Clinical Perspective.” Advances in Experimental Medicine and Biology 729 (January): 
83–94. doi:10.1007/978-1-4614-1222-9_6. 
Mohan, Jagan, Björn Morén, Elin Larsson, Mikkel R Holst, and Richard Lundmark. 2015. 
“Cavin3 Interacts with cavin1 and caveolin1 to Increase Surface Dynamics of 
Caveolae.” Journal of Cell Science 128 (5): 979–91. doi:10.1242/jcs.161463. 
Molnár, István Artúr, Béla Ákos Molnár, Laura Vízkeleti, Krisztina Fekete, Judit Tamás, 
Péter Deák, Csilla Szundi, et al. 2017. “Breast Carcinoma Subtypes Show Different 
Patterns of Metastatic Behavior.” Virchows Archiv 470 (3): 275–83. 
doi:10.1007/s00428-017-2065-7. 
Moren, B., C. Shah, M. T. Howes, N. L. Schieber, H. T. McMahon, R. G. Parton, O. 
Daumke, and R. Lundmark. 2012. “EHD2 Regulates Caveolar Dynamics via ATP-
Driven Targeting and Oligomerization.” Molecular Biology of the Cell. 
doi:10.1091/mbc.E11-09-0787. 
Morén, Björn, Claudio Shah, Mark T Howes, Nicole L Schieber, Harvey T McMahon, 
Robert G Parton, Oliver Daumke, and Richard Lundmark. 2012. “EHD2 Regulates 
Caveolar Dynamics via ATP-Driven Targeting and Oligomerization.” Molecular 
Biology of the Cell 23 (7): 1316–29. doi:10.1091/mbc.E11-09-0787. 
Nassoy, Pierre, and Christophe Lamaze. 2012. “Stressing Caveolae New Role in Cell 
Mechanics.” Trends in Cell Biology 22 (7). Elsevier Ltd: 381–89. 
doi:10.1016/j.tcb.2012.04.007. 
Nawaz, Z, D M Lonard, A P Dennis, C L Smith, and B W O’Malley. 1999. “Proteasome-
Dependent Degradation of the Human Estrogen Receptor.” Proceedings of the 
National Academy of Sciences of the United States of America 96 (5): 1858–62. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=26701&tool=pmcentrez
&rendertype=abstract. 
137 
 
Neve, Richard M., Koei Chin, Jane Fridlyand, Jennifer Yeh, Frederick L. Baehner, Tea 
Fevr, Laura Clark, et al. 2006. “A Collection of Breast Cancer Cell Lines for the 
Study of Functionally Distinct Cancer Subtypes.” Cancer Cell 10 (6): 515–27. 
doi:10.1016/j.ccr.2006.10.008. 
Nguyen-Ngoc, Kim-Vy, Eliah R. Shamir, Robert J. Huebner, Jennifer N. Beck, Kevin J. 
Cheung, and Andrew J. Ewald. 2015. “3D Culture Assays of Murine Mammary 
Branching Morphogenesis and Epithelial Invasion.” In , 135–62. doi:10.1007/978-1-
4939-1164-6_10. 
Okamoto, T, A Schlegel, P E Scherer, and M P Lisanti. 1998. “Caveolins, a Family of 
Scaffolding Proteins for Organizing ‘preassembled Signaling Complexes’ at the 
Plasma Membrane.” The Journal of Biological Chemistry 273 (10): 5419–22. 
http://www.ncbi.nlm.nih.gov/pubmed/9488658. 
Ortega-Cava, Cesar F, Srikumar M Raja, Zenab Laiq, Tameka a Bailey, Haitao Luan, 
Bhopal Mohapatra, Stetson H Williams, et al. 2011. “Continuous Requirement of 
ErbB2 Kinase Activity for Loss of Cell Polarity and Lumen Formation in a Novel 
ErbB2/Neu-Driven Murine Cell Line Model of Metastatic Breast Cancer.” Journal of 
Carcinogenesis 10 (January): 29. doi:10.4103/1477-3163.90443. 
Parton, Robert G, and Miguel A del Pozo. 2013. “Caveolae as Plasma Membrane 
Sensors, Protectors and Organizers.” Nature Reviews. Molecular Cell Biology 14 (2): 
98–112. doi:10.1038/nrm3512. 
Patani, Neill, Lesley-Ann Martin, Jorge S Reis-Filho, and Mitch Dowsett. 2012. “The Role 
of Caveolin-1 in Human Breast Cancer.” Breast Cancer Research and Treatment 131 
(1): 1–15. doi:10.1007/s10549-011-1751-4. 
Pekar, Olga, Sigi Benjamin, Hilla Weidberg, Silvia Smaldone, Francesco Ramirez, and 
Mia Horowitz. 2012. “EHD2 Shuttles to the Nucleus and Represses Transcription.” 
Biochemical Journal. doi:10.1042/BJ20111268. 
Pelkmans, L, J Kartenbeck, and A Helenius. 2001. “Caveolar Endocytosis of Simian Virus 
40 Reveals a New Two-Step Vesicular-Transport Pathway to the ER.” Nature Cell 
Biology 3 (5): 473–83. doi:10.1038/35074539. 
Pelkmans, Lucas, Thomas Bürli, Marino Zerial, and Ari Helenius. 2004. “Caveolin-
Stabilized Membrane Domains as Multifunctional Transport and Sorting Devices in 
Endocytic Membrane Traffic.” Cell 118 (6): 767–80. doi:10.1016/j.cell.2004.09.003. 
Pinilla, Socorro María Rodríguez, Emiliano Honrado, David Hardisson, Javier Benítez, 
and José Palacios. 2006. “Caveolin-1 Expression Is Associated with a Basal-like 
Phenotype in Sporadic and Hereditary Breast Cancer.” Breast Cancer Research and 
Treatment 99 (1): 85–90. doi:10.1007/s10549-006-9184-1. 
Posey, Avery D, Peter Pytel, Konstantina Gardikiotes, Alexis R Demonbreun, Mark 
Rainey, Manju George, Hamid Band, and Elizabeth M McNally. 2011. “Endocytic 
138 
 
Recycling Proteins EHD1 and EHD2 Interact with Fer-1-like-5 (Fer1L5) and Mediate 
Myoblast Fusion.” The Journal of Biological Chemistry 286 (9): 7379–88. 
doi:10.1074/jbc.M110.157222. 
Provenzano, P P, D R Inman, K W Eliceiri, and P J Keely. 2009. “Matrix Density-Induced 
Mechanoregulation of Breast Cell Phenotype, Signaling and Gene Expression 
through a FAK-ERK Linkage.” Oncogene 28 (49): 4326–43. doi:10.1038/onc.2009.299. 
Qian, Niansong, Takayuki Ueno, Nobuko Kawaguchi-Sakita, Masahiro Kawashima, 
Noriyuki Yoshida, Yoshiki Mikami, Tomoko Wakasa, et al. 2011. “Prognostic 
Significance of Tumor/stromal Caveolin-1 Expression in Breast Cancer Patients.” 
Cancer Science 102 (8): 1590–96. doi:10.1111/j.1349-7006.2011.01985.x. 
Rainey, Mark a, Manju George, GuoGuang Ying, Reiko Akakura, Daniel J Burgess, Ed 
Siefker, Tom Bargar, et al. 2010. “The Endocytic Recycling Regulator EHD1 Is 
Essential for Spermatogenesis and Male Fertility in Mice.” BMC Developmental 
Biology 10 (January): 37. doi:10.1186/1471-213X-10-37. 
Ringnér, Markus, Erik Fredlund, Jari Häkkinen, Åke Borg, and Johan Staaf. 2011. 
“GOBO: Gene Expression-Based Outcome for Breast Cancer Online.” PloS One 6 (3). 
Public Library of Science: e17911. doi:10.1371/journal.pone.0017911. 
Savage, Kay, Maryou B K Lambros, David Robertson, Robin L Jones, Chris Jones, Alan 
Mackay, Michelle James, et al. 2007. “Caveolin 1 Is Overexpressed and Amplified in 
a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, 
Ultrastructural, Immunohistochemical, and in Situ Hybridization Analysis.” 
Clinical Cancer Research : An Official Journal of the American Association for Cancer 
Research 13 (1): 90–101. doi:10.1158/1078-0432.CCR-06-1371. 
Savage, Kay, Samuel Leung, S Katrina Todd, Lindsay A Brown, Robin L Jones, David 
Robertson, Michelle James, et al. 2008. “Distribution and Significance of Caveolin 2 
Expression in Normal Breast and Invasive Breast Cancer: An Immunofluorescence 
and Immunohistochemical Analysis.” Breast Cancer Research and Treatment 110 (2): 
245–56. doi:10.1007/s10549-007-9718-1. 
Schilling, Jan M, and Hemal H Patel. 2015. “Non-Canonical Roles for Caveolin in 
Regulation of Membrane Repair and Mitochondria: Implications for Stress 
Adaptation with Age.” The Journal of Physiology, September. doi:10.1113/JP270591. 
Sengupta, Soma, Manju George, Katharine K Miller, Khurram Naik, Jonathan Chou, 
Mary Ann Cheatham, Peter Dallos, Mayumi Naramura, Hamid Band, and Jing 
Zheng. 2009. “EHD4 and CDH23 Are Interacting Partners in Cochlear Hair Cells.” 
The Journal of Biological Chemistry 284 (30): 20121–29. doi:10.1074/jbc.M109.025668. 
Senju, Yosuke, and Shiro Suetsugu. 2016. “Possible Regulation of Caveolar Endocytosis 
and Flattening by Phosphorylation of F-BAR Domain Protein PACSIN2/Syndapin 
II.” BioArchitecture, January, 00–00. doi:10.1080/19490992.2015.1128604. 
139 
 
Shah, Claudio, Balachandra G Hegde, Björn Morén, Elmar Behrmann, Thorsten Mielke, 
Gregor Moenke, Christian M T Spahn, Richard Lundmark, Oliver Daumke, and 
Ralf Langen. 2014. “Structural Insights into Membrane Interaction and Caveolar 
Targeting of Dynamin-like EHD2.” Structure (London, England : 1993) 22 (3): 409–20. 
doi:10.1016/j.str.2013.12.015. 
Shaw, Frances L., Hannah Harrison, Katherine Spence, Matthew P. Ablett, Bruno M. 
Simões, Gillian Farnie, and Robert B. Clarke. 2012. “A Detailed Mammosphere 
Assay Protocol for the Quantification of Breast Stem Cell Activity.” Journal of 
Mammary Gland Biology and Neoplasia 17 (2). Springer US: 111–17. 
doi:10.1007/s10911-012-9255-3. 
Shi, Yin, Shi-Hao Tan, Shukie Ng, Jing Zhou, Na-Di Yang, Gi-Bang Koo, Kerrie-Ann 
McMahon, et al. 2015. “Critical Role of CAV1/caveolin-1 in Cell Stress Responses in 
Human Breast Cancer Cells via Modulation of Lysosomal Function and 
Autophagy.” Autophagy 11 (5): 769–84. doi:10.1080/15548627.2015.1034411. 
Shi, Yuhua, Xiaobing Liu, Yongfang Sun, Dichen Wu, Aifeng Qiu, Haiyan Cheng, 
Cuigan Wu, and Xuebin Wang. 2015. “Decreased Expression and Prognostic Role of 
EHD2 in Human Breast Carcinoma: Correlation with E-Cadherin.” Journal of 
Molecular Histology 46 (2): 221–31. doi:10.1007/s10735-015-9614-7. 
Shiota, Takuya, Yuko Miyasato, Koji Ohnishi, Mutsuko Yamamoto-Ibusuki, Yutaka 
Yamamoto, Hirotaka Iwase, Motohiro Takeya, and Yoshihiro Komohara. 2016. 
“The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients 
with Breast Cancer.” Edited by Fabrizio Mattei. PLOS ONE 11 (11): e0166680. 
doi:10.1371/journal.pone.0166680. 
Siegel, Rebecca L., Kimberly D. Miller, and Ahmedin Jemal. 2017. “Cancer Statistics, 
2017.” CA: A Cancer Journal for Clinicians 67 (1): 7–30. doi:10.3322/caac.21387. 
Simone, Laura C, Naava Naslavsky, and Steve Caplan. 2014. “Scratching the Surface: 
Actin’ and Other Roles for the C-Terminal Eps15 Homology Domain Protein, 
EHD2.” Histology and Histopathology 29 (3): 285–92. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4106284&tool=pmcentr
ez&rendertype=abstract. 
Sinha, Bidisha, Darius Köster, Richard Ruez, Pauline Gonnord, Michele Bastiani, Daniel 
Abankwa, Radu V Stan, et al. 2011. “Cells Respond to Mechanical Stress by Rapid 
Disassembly of Caveolae.” Cell 144 (3): 402–13. doi:10.1016/j.cell.2010.12.031. 
Sohn, Jihee, Rachel M Brick, and Rocky S Tuan. 2016. “From Embryonic Development to 
Human Diseases: The Functional Role of Caveolae/caveolin.” Birth Defects Research. 
Part C, Embryo Today : Reviews 108 (1): 45–64. doi:10.1002/bdrc.21121. 
Stoeber, Miriam, Ina Karen Stoeck, Christine Hänni, Christopher Karl Ernst Bleck, 
Giuseppe Balistreri, and Ari Helenius. 2012. “Oligomers of the ATPase EHD2 
140 
 
Confine Caveolae to the Plasma Membrane through Association with Actin.” The 
EMBO Journal 31 (10): 2350–64. doi:10.1038/emboj.2012.98. 
Thomas, Nicholas B P, Iain R Hutcheson, Lee Campbell, Julia Gee, Kathryn M Taylor, 
Robert I Nicholson, and Mark Gumbleton. 2010. “Growth of Hormone-Dependent 
MCF-7 Breast Cancer Cells Is Promoted by Constitutive Caveolin-1 Whose 
Expression Is Lost in an EGF-R-Mediated Manner during Development of 
Tamoxifen Resistance.” Breast Cancer Research and Treatment 119 (3): 575–91. 
doi:10.1007/s10549-009-0355-8. 
Turtoi, Andrei, Arnaud Blomme, Akeila Bellahcène, Christine Gilles, Vincent 
Hennequière, Paul Peixoto, Elettra Bianchi, et al. 2013. “Myoferlin Is a Key 
Regulator of EGFR Activity in Breast Cancer.” Cancer Research 73 (17): 5438–48. 
doi:10.1158/0008-5472.CAN-13-1142. 
Wei, Spencer C, Laurent Fattet, Jeff H Tsai, Yurong Guo, Vincent H Pai, Hannah E 
Majeski, Albert C Chen, et al. 2015. “Matrix Stiffness Drives Epithelial-
Mesenchymal Transition and Tumour Metastasis through a TWIST1-G3BP2 
Mechanotransduction Pathway.” Nature Cell Biology 17 (5): 678–88. 
doi:10.1038/ncb3157. 
Wu, Xingrao, Ayesha Baig, Goulnar Kasymjanova, Kamran Kafi, Christina Holcroft, 
Hind Mekouar, Annie Carbonneau, Boris Bahoric, Khalil Sultanem, and Thierry 
Muanza. 2016. “Pattern of Local Recurrence and Distant Metastasis in Breast 
Cancer By Molecular Subtype.” Cureus, December. doi:10.7759/cureus.924. 
Yadav, Budhi S, Priyanka Chanana, and Swaty Jhamb. 2015. “Biomarkers in Triple 
Negative Breast Cancer: A Review.” World Journal of Clinical Oncology 6 (6): 252–63. 
doi:10.5306/wjco.v6.i6.252. 
Yamaguchi, Hideki, Yukiko Takeo, Shuhei Yoshida, Zen Kouchi, Yoshikazu Nakamura, 
and Kiyoko Fukami. 2009. “Lipid Rafts and Caveolin-1 Are Required for 
Invadopodia Formation and Extracellular Matrix Degradation by Human Breast 
Cancer Cells.” Cancer Research 69 (22): 8594–8602. doi:10.1158/0008-5472.CAN-09-
2305. 
Yang, Hong, Liuyuan Guan, Shun Li, Ying Jiang, Niya Xiong, Li Li, Chunhui Wu, 
Hongjuan Zeng, and Yiyao Liu. 2016. “Mechanosensitive Caveolin-1 Activation-
Induced PI3K/Akt/mTOR Signaling Pathway Promotes Breast Cancer Motility, 
Invadopodia Formation and Metastasis in Vivo.” Oncotarget, February. 
doi:10.18632/oncotarget.7583. 
Yang, Xiaojing, Hanru Ren, Li Yao, Xueyu Chen, and Aina He. 2015. “Role of EHD2 in 
Migration and Invasion of Human Breast Cancer Cells.” Tumour Biology : The 
Journal of the International Society for Oncodevelopmental Biology and Medicine 36 (5): 
3717–26. doi:10.1007/s13277-014-3011-9. 
141 
 
  
 
 
 
 
Appendix  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
142 
 
 
CHIP/STUB1 ubiquitin ligase targets MZF1 and loss of CHIP in breast cancer 
unleashes the MZF1-cathepsin pro-oncogenic program 
Haitao Luan1,2,$, Bhopal C. Mohapatra1,3,$, Timothy A. Bielecki1,$, Sameer Mirza2, Tameka 
A. Bailey1,*, Robert J. Clubb1,*, Wei An1,2, Dena Ahmed7, Matthew D. Storck1, Yuri 
Sheinin4,6, Jane L. Meza5,6, Srikumar M. Raja1,*, Emad A. Rakha7, Vimla Band1,2,3,6, Hamid 
Band1,2,3,4,6,# 
1Eppley Institute for Research in Cancer and Allied Diseases; Departments of 2Genetics, 
Cell Biology & Anatomy, 3Biochemistry & Molecular Biology, and 4Pathology & 
Microbiology, College of Medicine; 5Department of Biostatistics, College of Public 
Health; and 6Fred & Pamela Buffett Cancer Center, University of Nebraska Medical 
Center, NE 68198, USA; 7Department of Pathology, University of Nottingham and 
Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 
1PB, UK. 
*Current Addresses: TAB, Department of Biology, University of Arkansas, Fayetteville, 
AR, USA; RC, Department of Oncology, Novartis Molecular Diagnostics, LLC, 
Cambridge, MA, USA; SMR, Robert H Lurie Comprehensive Cancer Center, 
Northwestern University, Chicago, IL, USA. 
$Co-First Authors 
Running title: Loss of CHIP E3 unleashes cathepsin expression 
Keywords: CHIP/STUB1, ubiquitin ligase, breast cancer, ErbB2, matrix degradation 
Financial support: Supported by the NIH grants CA116552 to HB, and CA96844 and 
CA144027 to VB; DOD grants W81WH-11-1-0167 to HB, and W81XWH-07-1-0351 and 
W81XWH-11-1-0171 to VB; NIGMS (NIH) Institutional Development Award P30 
GM106397; and support to the Confocal, Flow Cytometry and other Cores from the NCI 
Cancer Center Support Grant (P30CA036727) to FPBCC and from Nebraska Research 
Initiative. TA Bielecki and TA Bailey were trainees under a NCI Cancer Biology Training 
Grant (T32CA009476). HL received a China Scholarship Council graduate fellowship. 
BCM and WA received UNMC graduate fellowships. TA Bailey was a Susan G. Komen 
Foundation postdoctoral fellow. 
#Corresponding Author: Hamid Band, MD, PhD. Eppley Institute for Research in 
Cancer and Allied Disease, 985950 Nebraska Medical Center, Omaha, NE 68198-5950, 
USA; Email: hband@unmc.edu; Phone: 402-559-8572; FAX: 402-559-4651 
Conflict of interest disclosure statement: None of the authors declare any conflicts. 
Word count: Abstract - 249; Manuscript – 4,995  
143 
 
 Abstract: 
Biochemical pathways whose rewiring is required for tumor progression 
represent potential targets to devise new combinatorial therapies. CHIP/STUB1 
ubiquitin ligase is a negative co-chaperone of HSP90/HSC70, and its expression is 
reduced or lost in several cancers, including breast cancer. Using an extensive and well-
annotated breast cancer tissue collection, we identified the loss of nuclear but not 
cytoplasmic CHIP to predict more aggressive tumorigenesis and poorer patient survival, 
with loss of CHIP in two-thirds of ErbB2+ and triple-negative breast cancers and in one-
third of ER+ breast cancers. Reduced CHIP expression was seen in breast cancer patient-
derived xenograft tumors and in ErbB2+ and triple-negative breast cancer cell lines. 
Ectopic CHIP expression in ErbB2+ lines suppressed in vitro oncogenic traits and in vivo 
xenograft tumor growth. An unbiased screen for CHIP-regulated nuclear transcription 
factors identified a number of candidates whose DNA-binding activity is up- or down-
regulated by CHIP. We validated Myeloid Zinc Finger 1 (MZF1) as a CHIP target as it 
has emerged as a key positive regulator of cathepsin B/L (CTSB/L)-mediated tumor cell 
invasion downstream of ErbB2. We show that CHIP negatively regulates CTSB/L 
expression in ErbB2+ and other breast cancer cell lines. CTSB inhibition abrogates 
invasion and matrix degradation in vitro and halts ErbB2+ breast cancer cell line 
xenograft growth. We conclude that loss of CHIP remodels cellular transcriptome to 
unleash critical pro-oncogenic pathways, such as the matrix-degrading enzymes of the 
cathepsin family, whose components can provide new therapeutic opportunities in 
breast and other cancers with loss of CHIP expression.   
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Introduction 
The ubiquitin-proteasome system (UPS) plays diverse roles in normal cellular 
homeostasis.  Ubiquitination cascade involves two ubiquitin-activating (E1) enzymes, a 
small group of ubiquitin-conjugating (E2) enzymes and a large repertoire of ubiquitin 
ligase (E3) enzymes. E3s dictate substrate specificity and comprise two broad groups: 
the human papilloma virus E6-interacting (HECT) domain and the really interesting 
new gene (RING) finger domain protein families (1). 
Consistent with roles of the UPS as a contributor to oncogenesis, certain cancers, 
e.g., multiple myeloma, are clinically treated with proteasome inhibitors (1). Recent 
focus has shifted to substrate-specific elements of the UPS, such as E3s, with MDM2 
inhibitors currently in clinical trials for several malignancies (clinicaltrials.gov). Notably, 
mutations of E3s, such as CBL (2) or FBW7 (3) convert them into oncogenes. 
The C-terminus of HSC70-Interacting Protein (CHIP)/STIP1 homology and U-
Box containing protein 1 (STUB1) is a U-box subfamily RING finger type E3 that 
regulates protein quality control as a negative co-chaperone of the HSP90/HSC70 
chaperone by targeting unfolded or misfolded proteins for proteasomal degradation (4-
9). CHIP-null mice exhibit strain-dependent embryonic lethality and hyper-sensitivity to 
stresses (10). CHIP also targets many mature proteins for ubiquitination and 
proteasomal degradation or degradation-independent regulation (11).  
CHIP targeting of oncogenic driver/co-drivers, such as ErbB2, has prompted 
analyses of CHIP expression in human tumors. Analysis of matched normal and tumor 
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tissues from 27 breast cancer patients revealed progressive loss of CHIP mRNA 
expression with tumor progression; CHIP knockdown in CHIP-high MCF-7 (ER+) cells 
increased and CHIP overexpression in CHIP-low MDA-MB231 (triple-negative; TN) 
cells suppressed oncogenic traits in vitro and xenograft tumor growth and metastasis in 
vivo (12). Another study of 33 normal and 127 breast tumor samples also showed an 
inverse relation of CHIP mRNA levels with increasing grade and Nottingham 
Prognostic Index (13). A third study of 183 patient found an inverse correlation between 
ErbB2 and CHIP protein levels, with reduced CHIP expression associated with tumor 
progression (14). Thus, CHIP appears to function as a suppressor of breast cancer 
tumorigenesis. However, the extent of loss of CHIP expression in breast cancer subtypes 
is unknown. 
Mechanistically, CHIP can target cell surface, cytoplasmic, nuclear or secreted 
proteins for ubiquitin-dependent degradation (11). Relevant to breast cancer, CHIP 
targets ERB2 (15-17), SRC-3 transcriptional coactivator (12), macrophage inhibitory 
factor (18), protein kinase 6/breast tumor kinase (19) and actin regulatory protein 
profilin-1 (20).  However, how loss of CHIP promotes oncogenesis remains unclear. 
Here, we assessed both nuclear and cytoplasmic CHIP expression in a well-
annotated cohort of >900 breast cancer specimens. We show that a majority of ERBB2+ 
and TN, and a minority (but numerically large number) of ER+ breast cancers show loss 
of CHIP expression, and that loss of the nuclear and not the cytoplasmic CHIP 
expression predicts features of tumor progression and invasion, and poor patient 
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survival. Loss of CHIP expression in ERBB2+ breast tumor cell lines unleashes a 
program of increased tumor cell invasion and migration in vitro and tumorigenesis in 
vivo, as reported with a TN cell line model (12). Given the importance of the loss of 
nuclear CHIP, we performed an unbiased screen of the impact of low vs. high CHIP 
levels on DNA-binding activities of cellular transcription factors in ERBB2+ and TN 
breast cancer cell lines and identified a number of shared CHIP-regulated transcription 
factors. Here, we focus on CHIP regulation of MZF1 as it was recently identified as a key 
mediator of pro-invasive signaling downstream of ERBB2 through upregulation of the 
expression of matrix degrading cathepsin B and L enzymes (21). We show the CHIP 
dependence of this pathway in cell lines representing various breast cancer subtypes 
and demonstrate that chemical targeting of CTSB inhibits ERBB2-driven tumorigenesis. 
We conclude that loss of CHIP expression unleashes a MZF1-dependent and CTSB/L-
mediated pro-oncogenic pathway in breast cancer. 
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Materials and Methods 
Details methods are presented in Supplementary Methods.  
Cell culture: ErbB2-overexpressing breast cancer cell lines SKBR3 and BT474 (ATCC) 
were cultured in complete α-MEM medium with 5% fetal bovine serum, 10 mM HEPES, 
1 mM each of sodium pyruvate, nonessential amino acids and L-glutamine, 50 µM 2-
ME, and 1% penicillin/ streptomycin (Life technologies, Carlsbad, CA). ErbB2-
overexpressing breast cancer cell line 21MT1 (22) was cultured α-MEM medium 
supplemented as above and with 1 µg/mL hydrocortisone and 12.5 ng/mL epidermal 
growth factor (Sigma-Aldrich, St. Louis, MO). The lentiviral packaging cell line TSA-54 
(23), the ER+ breast cancer cell line MCF7 and the ErbB2-negative and estrogen 
receptor/progesterone receptor-negative (TN) breast cancer cell line MDA-MB-231 
(ATCC) were cultured in DMEM medium (Life technologies) and supplements as for 
BT474. For retroviral overexpression of Myc-tagged human CHIP (16), HEK-293T cells 
were transfected with pMSCV-CHIP and packaging vectors, and supernatants used to 
infect ErbB2+ breast cancer cell lines followed by selection in puromycin. Cell lines were 
regularly tested for mycoplasma. Cell lines were not continuously cultured for >3 
months. 
Antibodies and Reagents: Rabbit anti-CHIP antibody used for blotting has been 
described (16). Other primary antibodies or secondary conjugates for fluorescence or 
immunoblotting analyses are described under Supplementary Methods.  
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Cell lysis, immunoprecipitation and immunoblotting: Cells lysates were prepared in 
RIPA or Triton X-100 lysis buffers (as indicated in figure legends) and used for 
immunoprecipitation and immunoblotting analyses as described in Supplementary 
Methods. 
Quantitative real-time PCR: Total RNA extracted using TRIzol reagent (Invitrogen) and 
reverse transcribed using Quantitative real-time PCR kit (cat. 204141, Qiagen, 
Germantown, MD) was used for real-time QPCR with primers described in 
Supplementary Methods.  
Cell growth assays: Cell growth was analyzed as cumulative proliferation over 5 serial 
weekly passages and by soft agar anchorage-independent growth assay as described 
under Supplementary Methods. 
 Transwell migration and invasion assays: The migration or invasion of cells was 
analyzed using uncoated or Matrigel-coated Transwell chambers as described under 
Supplementary Methods.  
Extracellular matrix (ECM) degradation assay: This assay was carried out using QCM™ 
Gelatin Invadopodia kit (Cat. ECM670, EMD Millipore, Billerica, MA) according to the 
manufacturer’s protocol. Details are presented in Supplementary Methods. ECM 
degradation, seen as focal loss of fluorescent signal (“holes”) in the labeled gelatin layer 
was quantified using Image J (NIH).  
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Xenograft tumorigenesis: 106 cells in Matrigel (BD Biosciences) were implanted in the 
mammary fat pad of female NSG mice (The Jackson Laboratory) primed with s/c 
estrogen pellet (0.72 mg/ 60 day pellets; Innovative Research of America, Sarasota, FL) 
and tumor growth monitored weekly for 10 weeks.   After euthanasia, tumors were 
imaged, and formalin-fixed and paraffin-embedded for further analyses. Details are 
presented in Supplementary Methods. 
Protein/DNA array: A protein/DNA combo-array kit (Cat. MA1215, Affymetrix, Santa 
Clara, CA) was used to simultaneously screen 345 transcription factors for DNA-binding 
activity per vendor protocol with signals detected using chemiluminescence (See 
Extended Methods). 
Electrophoretic mobility shift assay (EMSA): EMSA was carried out using an EMSA kit 
(cat. 20148, Life Technologies, Waltham, MA) as described in Extended Methods.  
Cathepsin B (CTSB)/Cathepsin L (CTSL) activity assay: CTSB/L activity was assayed 
using the Magic Red CTSB/L Activity Kit (Cat. 937 & 941, Immunochemistry 
Technologies, Bloomington, MN) according to the manufacturer’s protocol (See 
Extended Methods). Experiments were run in triplicates and repeated thrice. Ten 
random fields per well were imaged and the fluorescence intensity was quantified using 
Image J (NIH).  
Human and animal subjects: The use of human tissues was approved by the Ethics 
Committee of the University of Nottingham. Mouse studies were pre-approved by the 
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UNMC Institutional Review Board (IRB) Committee, in compliance with Federal and 
State guidelines. 
IHC analysis of breast cancer tissue microarrays:  Tissue microarrays (TMAs) 
corresponding to a well-annotated 971 breast cancer patient cohort at the University of 
Nottingham Hospital Breast Unit and a commercial TMA (BR20837, from US Biomax, 
INC.) were analyzed by IHC staining (see Extended Methods for details) with a 
previously described (27) anti-rabbit CHIP antibody that was further validated 
(Supplementary Figure 1). 
Semi-quantitative assessment of staining intensity utilized a modified 
histochemical score (H-score) ranging from 0 to 300 based on multiplying staining 
intensity of 0 to 3 (negative, 0); weak, 1; moderate, 2; strong, 3) by the percentage of 
positive cells (See Extended Methods. Nuclear expression of >1 or cytoplasmic 
expression of >110 was considered positive (See Extended Methods). The IHC staining 
results were statistically analyzed using the SPSS 16.0 statistical software (SPSS Inc., 
Chicago, IL, USA) (See Extended Methods).  
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Results 
Reduced nuclear CHIP expression in breast cancer correlates with tumor progression, 
invasion and poorer patient survival 
As small previous studies (12-14) have not clarified which breast cancer subtypes 
lose CHIP expression, we performed immunohistochemistry (IHC) analysis of formalin-
fixed and paraffin-embedded tissue microarrays (TMAs) from a well-annotated cohort 
of 971 breast cancer patients (Supplementary Table 1) (24-28) using an established rabbit 
anti-CHIP antibody (16) further validated in western blotting with lysates of CHIP-
depleted or ectopic CHIP-expressing cell lines (Supplementary Figure S1). Initial IHC of 
a commercial breast cancer TMA (208 samples) detected both cytoplasmic and nuclear 
CHIP within tumor cells and in surrounding normal epithelium (Figure 1A). In the 971-
sample TMA, 423 and 314 samples, respectively, were evaluable for cytoplasmic and 
nuclear staining, with multiple staining patterns: low cytoplasmic/low nuclear, low 
cytoplasmic/high nuclear, high cytoplasmic/low nuclear; or high cytoplasmic/high 
nuclear (Figure 1B; Supplementary Table1). Loss of nuclear CHIP staining showed a 
significant positive correlation with biochemical markers of tumor progression and 
metastasis, reduced ER and PR staining, altered cytokeratins (CK 18, CK19), increased 
expression of early epithelial-mesenchymal transition markers (N-cadherin, P-cadherin) 
and expression of EGFR family proteins (EGFR, ErbB2, ErbB4) (Supplementary Table 2). 
Only CK 18 (p=0.001) and ErbB2 (p=0.016) expression correlated with reduced 
cytoplasmic CHIP staining (Supplementary Table 2). Lower nuclear but not cytoplasmic 
152 
 
CHIP staining showed a significant positive correlation with clinical-pathological 
features of tumor progression (higher tumor size, tumor grade, pleomorphism and 
mitotic status) (Supplementary Table 1). Using the previously-established ER, PR and 
ErbB2/Her2 expression status of the TMA samples (25-29), low CHIP expression was 
seen in two-thirds of ErbB2+ and TN cases and about one-third of ER+ cases. Kaplan-
Meier analysis revealed that low nuclear but not the cytoplasmic staining pattern 
correlated significantly with poorer breast cancer-specific survival (Nuclear CHIP, 
p=0.003 Vs. cytoplasmic CHIP, p=0.469; Figure 1C). 
 
CHIP suppresses tumorigenic traits in ErbB2+ breast cancer cell lines 
Validating IHC results, a majority of cell lines representing the ErbB2+ and TN 
breast cancer subtypes showed lower CHIP mRNA and protein levels compared to ER+ 
lines (Supplementary Figure 2A and 2B); the ER+ and TN cell line results confirm a 
previous report (12). Western blotting of 12 breast cancer patient-derived xenograft (29) 
lysates confirmed the lower or absent CHIP expression in TN, ErbB2+ and some ER+ 
breast cancers (Supplementary Figure 2C). The CHIP expression status in the 
commercial TMA was consistent with these results (Supplementary Figure 2D). 
To gain mechanistic insights into how the loss of nuclear CHIP promotes 
oncogenic progression, we utilized ErbB2+ breast cancer cell lines (BT474, SK-BR3 and 
21-MT1) as primary models, confirming key findings in TN (MDA-MB231) and ER+ 
(MCF-7) lines. We engineered 3 ErbB2+ lines and MDA-MB231 cells to stably 
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overexpress Myc-CHIP (CHIP-hi lines) (or vector control; CHIP-lo lines) and MCF-7 
cells with CHIP shRNA (CHIP-lo) to deplete the endogenous CHIP expression (or a 
control shRNA; CHIP-hi) (Supplementary Figure 1). As CHIP expression in MDA-MB-
231 cells is known to suppress oncogenic attributes (12), these served as controls. 
While no significant differences in cell proliferation were observed over a single 
passage, confirming previous MDA-MB231 results (12), cumulative cell proliferation 
over multiple passages was modestly but significantly lower in CHIP-hi vs. control cells 
(Figure 2A). CHIP-high cells exhibited a significantly lower number of colonies in soft 
agar compared to control cells (Figure 2B). CHIP-hi cells exhibited significantly reduced 
Transwell migration (Figure 2C). Finally, CHIP-hi 21MT1 cells exhibited significantly 
reduced invasion through Matrigel compared to CHIP-lo control cells (Figure 2D).  
Analysis of CHIP-lo vs. CHIP-hi MDA-MB231 cells, as controls, confirmed the 
expected reduction in primary tumor growth and lung metastasis upon CHIP 
overexpression (12) (Supplementary Figure 3). Notably, the CHIP-hi BT474 cells formed 
significantly smaller xenograft tumors compared to those with CHIP-lo cells (Figure 3A 
and 3B). Exogenous CHIP overexpression in tumors was confirmed by western blotting 
(Figure 3C). Histologically, the CHIP-hi BT474 tumors showed lower nuclear atypia and 
mitotic index (Figure 3D), and reduced Ki67+ proliferating cells (Figure 3E and 3F) 
compared to CHIP-lo BT474 tumors. No significant difference in immunostaining for the 
apoptotic marker cleaved-caspase 3 was noted (Figure 3E and 3G), suggesting a 
primarily cytostatic impact of CHIP overexpression. These studies support the tumor 
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suppressor role of CHIP in ErbB2+ breast cancer as suggested by our clinical-
pathological analyses. 
 
Identification of nuclear targets of CHIP in breast cancer 
As loss of nuclear but not cytoplasmic CHIP expression predicted tumor 
progression and poor patient outcomes, we assessed the cognate DNA-binding activities 
of 345 cellular transcription factors in nuclear extracts of control vs. CHIP-hi ErbB2+ 
BT474 cells, using a commercially-available array platform, expressing the DNA-binding 
activity in CHIP-hi over CHIP-lo extracts as a fold ratio. Subsets of transcription factors 
showed changes in DNA-binding activities outside of the arbitrary 3-fold cut-off, 
representing potential direct or indirect targets of negative or positive regulation by 
CHIP (Figure 4A, left). These (Supplementary Table 3) included known CHIP targets, 
such as p53 and NFkB (30, 31) validating the approach. Analysis of CHIP-hi vs. CHIP-lo 
(control) MDA-MB231 cells (Fig 4A, right) showed that most CHIP targets were shared 
with the BT474 cell model (see Supplementary Table 4) (Fig 4A), although the extent of 
changes differed. Thus, our unbiased screen identified novel CHIP-targeted 
transcription factors whose deregulated function upon loss of CHIP expression may 
contribute to tumor progression. 
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MZF1 is a direct target of CHIP-mediated ubiquitination and degradation 
We focused further on myeloid zinc finger 1 (MZF1), whose DNA-binding 
activity was down-regulated in CHIP-hi BT474 and MDA-MB231 cells (Figure 4A and 
6A; MZF1 highlighted in red), as it was recently identified as a nexus of ErbB2 signaling 
that culminates in tumor cell invasiveness through increased transcription of matrix-
degrading enzymes cathepsin B (CTSB) and L (CTSL) (21). Electrophoresis mobility shift 
assay (EMSA) using sequences corresponding to MZF1 binding sites on the CD34 gene 
promoter (32) confirmed reduced binding activity (shifted bands) in CHIP-hi vs. CHIP-
lo BT474 cells (Figure 4B). The MZF1 mRNA level was reduced in CHIP-hi vs. CHIP-lo 
cells BT474 cells (Figure 4C), suggesting the regulation of upstream modulators of MZF1 
transcription as part of CHIP-dependent reduction in DNA-binding activity. MZF1 
protein level was reduced in CHIP-hi vs. CHIP-lo cells, and anti-ubiquitin blotting of 
MZF1 immunoprecipitations showed increased MZF1 ubiquitination in CHIP-hi vs 
CHIP-lo BT474 cells (Figure 4D). Co-transfection of CHIP and MZF1 in HEK-293T cells 
revealed CHIP dose-dependent MZF1 ubiquitination (Figure 4E, upper) and reduction 
in protein level (Figure 4E, bottom). These results support the conclusion that MZF1 is a 
bona-fide target of CHIP, involving indirect transcriptional downregulation and CHIP-
dependent ubiquitination and degradation of MZF1. 
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CHIP is a negative regulator of MZF1-dependent and Cathepsin B/L-mediated ECM 
degradation 
CTSB/L are key regulators of tumor invasion, angiogenesis and metastasis (33), 
and their MZF1-dependent transcriptional upregulation was shown to mediate in vitro 
tumor cell invasion upon ErbB2 overexpression in breast cancer cells (21). We therefore 
asked if CHIP regulation of MZF1 translates into control of CTSB/L expression. EMSA 
with a DNA probe from a known MZF1-binding site in the CTSB promoter (32) 
confirmed reduced DNA-binding activity in the nuclear extracts of CHIP-hi vs. control 
ErbB2+ cells (Figure 5A), with reduced CTSB and CTSL mRNA and protein levels 
(Figure 5B and 5C), reduced CTSB/L enzymatic activities (Figure 5D-F) measured with a 
fluorescent substrate (34), and reduced FITC-labeled gelatin degradation (35, 36) (Figure 
5G and 5H). Thus, the MZF1/CTSB/L pro-invasion signaling axis is negatively regulated 
by CHIP in ErbB2+ breast cancer cells. 
Consistent with CHIP-dependent reduction in the DNA-binding activity of 
MZF1 in CHIP-hi vs. CHIP-lo MDA-MB231 cells (Figure 4A), reduced mRNA and 
protein levels of CTSB/L (Figure 6A and 6B), reduced CTSB/L activity (Figure 6C, 6D 
and 6E) and reduced florescent gelatin degradation (Figure 6F and 6G) were observed in 
CHIP-hi vs. CHIP-lo MDA-MB231 cells. Increased CTSB expression was also seen in 
CHIP KD vs. control MCF7 cells (Supplementary Figure 4).  Treatment of CHIP-lo 
21MT1 cells (high CTSB/L activity; Figure 6D and 6E) with CA074, a specific inhibitor of 
CTSB (37), abrogated fluorescent gelatin degradation, and markedly inhibited the 
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transwell invasion of 21MT1 (Figure 7A-C) and MDA-MB-231 (7D-F) breast cancer cell 
lines. Thus, we conclude that loss of CHIP expression across breast cancer subtypes 
upregulates the pro-invasive MZF1-CTSB/L signaling axis. 
To assess if the upregulation of CTSB expression and activity as a result of CHIP 
downregulation contributes to oncogenesis in vivo, we grew BT474 xenograft tumors to 
an average of 0.5 mm3 and treated the mice with CA074 (25 mg/Kg body weight, i.p.), 
Trastuzumab (4 mg/Kg, tail vein injection) as a standard ErbB2-targeted therapeutic or 
the vehicle control, based on previously used dosages (37-39). CA074 treatment led to a 
marked and statistically-significant inhibition of tumor growth at multiple time points, 
comparable to that seen with Trastuzumab (Figure 7G), supporting the conclusion that 
one mechanism by which loss of CHIP promotes breast tumor progression is by 
eliminating the negative regulation of MZF1 and unleashing the cathepsin expression. 
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Discussion 
Loss of expression of the HSP90/HSC70 co-chaperone CHIP E3 has emerged as a 
mechanism to promote tumor progression. Here, we demonstrate that loss of nuclear, 
and not cytoplasmic, CHIP expression is associated with tumor progression and shorter 
survival in breast cancer patients, and is a feature of about two-thirds of ErbB2+ and TN 
as well as a third of ER+ breast cancers. Importantly, we identify loss of CHIP as a key 
mechanism to alter the DNA-binding activities of a substantial subset of cellular 
transcription factors, and establish that loss of CHIP expression unleashes a pro-invasion 
signaling cascade in which the CHIP target MZF1 promotes cathepsin B and L 
expression. Using a chemical inhibitor strategy, we show that upregulation of MZF1-
CTSB axis due to loss of CHIP expression contributes to tumorigenesis. 
IHC analyses of an extensive collection of well-annotated breast cancer TMAs 
demonstrated that loss of nuclear CHIP signals correlates with markers of advanced 
tumor progression, including higher tumor grade, mitotic index and markers of early 
EMT (Supplementary Table 1), and significantly shorter breast cancer-specific and 
progression-free survival (Figure 1C). Loss of nuclear CHIP was a feature of nearly two-
thirds of ErB2+ and TN subtypes, consistent with their poorer intrinsic patient outcomes 
and higher metastatic odds (40, 41), and about a third of ER+ breast cancers 
(Supplementary Table 2). In contrast, loss of cytoplasmic CHIP expression was only 
associated with ErbB2 positivity, and did not predict poor patient survival (Fig 1C). 
These results materially extend previous findings using smaller patient cohorts (12-14), 
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and highlight the subtype preference of CHIP loss and the importance of the loss of 
nuclear CHIP as a pro-oncogenic adaptation in breast cancer. Of note, the CHIP-low ER+ 
patients numerically exceed the CHIP-lo ErbB2+ and TN patients, and further studies 
are needed to assess if these patients belong to a particular molecular sub-class. 
 Analyses in breast cancer cell lines confirmed the predominant loss of CHIP 
expression in the ErbB2+ and TN subtypes. Using matched pairs of ErbB2+ breast cancer 
cell lines with low endogenous CHIP expression vs. their CHIP-hi derivatives in 
functional assays, we show that CHIP levels are a key determinant of ErbB2-driven cell 
growth and invasiveness in vitro and xenograft tumor growth in nude mice, extending 
previous findings using CHIP-reconstituted MDA-MB231 (TN) and CHIP-depleted 
MCF-7 (ER+) lines (12), which served as controls. While we confirmed the lack of impact 
of CHIP restoration on cell proliferation in a single passage (12), analyses over multiple 
passages revealed a subtle but significant proliferative disadvantage (Figure 2A), which 
is profound under anchorage-independent conditions (Figure 2B). Thus, CHIP serves as 
a tumor suppressor for ErbB2+, TN and a proportion of ER+ breast cancers. 
Furthering our novel findings that loss of nuclear and not cytoplasmic CHIP 
correlates with tumor progression, an unbiased protein/DNA array screen identified a 
number of transcription factors whose DNA-binding activities are directly or indirectly 
up- or down-regulated by CHIP (Figure 4A), vastly expanding the list of potential 
targets of CHIP in the context of cancer (30, 31). Here, we have focused on MZF1, whose 
activity was downregulated by CHIP, since it was recently identified as a major 
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transcriptional activator of CTSB/L-mediated tumor cell invasion downstream of ErbB2 
in breast cancer cells (42). CTSB/L are overexpressed in primary breast cancers and CTSB 
or MZF1 knockdown abrogated breast cancer cell invasiveness in vitro (42).  Our EMSA 
analyses confirmed the reduced MZF1DNA-binding activity in CHIP-hi breast cancer 
cells (Figure 4B), and we show that MZF1 is both a direct target of CHIP for 
ubiquitination and destabilization (Figure 4D) and also indirectly regulated at the 
mRNA level, potentially due to CHIP regulation of upstream regulators of MZF1 
expression such as MYC (43) (Figure 4A). Since intermediary kinases (CDC42BPβ, ERK2, 
PAK4, PKCα) were implicated in MZF1-mediated CTSB/L transcription downstream of 
ErbB2 (42), negative regulation of these kinases or ErbB2 (15, 16) may also contribute to 
CHIP regulation of MZF1. 
Our analyses support a key role of loss of CHIP as a mechanism to unleash the 
MZF1-dependent transcriptional network that controls CTSB/L expression (Figure 5A) 
and extracellular matrix (ECM) degradation (Figure 5G), and to promote oncogenesis 
(Figure 2). CTSB is a well-established downstream mediator of invasive/metastatic 
signaling in various cancers (44, 45), including breast cancer (21, 37). Specific CTSB 
inhibition with CA074 reduced the matrix degradation and cell invasion in vitro and 
tumor growth in vivo (Figure 6), providing further support for loss of CHIP expression 
as a key breast cancer adaptation to unleash the pro-oncogenic MZF1-CTSB pathway. 
The strong effect of CTSB inhibition alone on matrix degradation and xenograft tumor 
growth, the latter comparable to Trastuzumab (Figure 7D), suggests that CTSB may be 
the dominant player in BT474 cells, consistent with strong reported impact of CTSB 
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depletion on in vitro invasiveness of ErbB2+ breast cancer cell lines (42). However, 
further studies to assess the contribution of CTSL and other potential targets of MZF1 
are warranted. Our in vitro results in TN and ER+ cell lines (Figure 4) also support the 
unleashing of MZF1-CTSB/L pathway in the corresponding breast cancer subtypes, and 
further studies in these and other tumors with loss of CHIP expression (11) will be of 
interest. 
In conclusion, our studies demonstrate that upregulation of MZF1/CTSB/L axis is 
an important pro-oncogenic mechanism unleashed by loss of CHIP expression in breast 
cancer. Given the established roles of cathepsins in matrix remodeling, invasion, 
angiogenesis and metastasis (44, 45), future studies to establish the role and targeting of 
MZF1-CTSB/L axis in metastatic tumor settings may provide new therapeutic 
opportunities for breast and other tumors with loss of CHIP expression (31, 46-49). 
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Figure 1. Reduced nuclear CHIP staining in primary breast cancer tissue microarrays 
(TMAs) specimens. (A) Anti-CHIP IHC staining of a representative breast cancer 
specimen vs. normal breast tissue to show cytoplasmic and nuclear staining. B. 
Representative IHC staining patterns of loss of nuclear vs. cytoplasmic CHIP expression 
in breast cancer TMAs. (C) Kaplan-Meier analysis of the correlation of breast cancer-
specific survival (BCSS) with reduction in nuclear (left) or cytoplasmic (right) CHIP 
expression. Number of patients and p values are indicated. 
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Figure 2. Suppression of in vitro oncogenic attributes of CHIP-lo ErbB2+ breast cancer 
cell lines upon CHIP overexpression. (A) Cumulative proliferation of CHIP-lo control 
(MSCV-puro) vs. CHIP-hi (MSCV-CHIP) 21MT1, BT474 and SKBR3 cell lines. (B) 
Anchorage-independent cell growth in soft agar after 3 weeks of culture. Y-axis, number 
of colonies per 2500 cells. (C) Transwell migration assay.  Y-axis, number of migrated 
cells per high power field (HPF). D. Transwell Matrigel-invasion assay. Y-axis, number 
of migrated cells per HPF.  Data are mean +/- SEM of 3 experiments, each in triplicates. 
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Figure 3. Reduced xenograft growth of CHIP-overexpressing BT474 cells in nude 
mice. (A) Tumor volume of CHIP-lo (MSCV-puro) control and CHIP-hi (MSCV-CHIP) 
BT474 xenografts over time N = 6 per group. *, p <0.05. (B) Photograph of resected CHIP-
lo (upper) and CHIP-hi (lower) BT474 cells. (C) Western blotting of endogenous and 
overexpressed (Myc-tagged) CHIP in resected BT474 xenografts; HSC70, loading 
control. (D & E) Representative H&E staining (D) or Ki67 (brown) plus cleaved caspase 3 
(CC3; red) staining of CHIP-lo (left) and CHIP-hi (right) BT474 xenograft tumor sections. 
(F, G) Quantification of Ki67 (F) and CC3 (G) positive cells in Figure E. Mean +/- SD, n=6.  
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Figure 4. Identification of MZF1 as a CHIP-regulated transcription factor in ErbB2+ 
breast cancer cells. (A) DNA-binding activities of 345 transcription factors were 
analyzed in CHIP-lo (MSCV-puro control) vs. CHIP-hi (MSCV-CHIP) BT474 and MDA-
MB-231cell lines. Y-axis, log-fold binding in CHIP-hi over CHIP-lo cells. The 3-fold 
increase (upper) or decrease (lower) in binding (dotted lines) was used as cut-off. MZF1 
(Open symbol). (B) Biotin-labeled MZF1-specific DNA sequences was used as to probe 
nuclear extracts of CHIP-hi (MSCV-CHIP, C) vs. CHIP-lo (MSCV-puro, P) BT474 cells. 
200-fold excess of non-labeled probe served as competitor. (C) Real-time qPCR analysis 
of MZF1 mRNA levels in CHIP-hi vs. CHIP-lo BT474 cells. (D) Immunoblotting of MZF1 
protein levels in CHIP-hi vs. CHIP-lo BT474 cells. (E) CHIP-dependent ubiquitination 
and degradation of MZF1. Anti-MZF1 immunoprecipitations from lysates of HEK-293T 
cells transfected with GFP- MZF1 +/- Myc- CHIP (0.5 or 4 g) w ere im m unoblotted  for 
ubiquitin or MZF1 (upper panel), and whole cell lysates (lower panel) for MZF1, CHIP 
or HSC70 (loading control).  
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Figure 5. CHIP levels control the expression of MZF1 target genes cathepsins B and L. 
(A) EMSA analysis with CTSB promoter sequences in CHIP-hi vs. CHIP-lo BT474 cells 
was done as in Figure 4B. (B) CTSB/L mRNA expression in CHIP-hi vs. CHIP-lo BT474 
cells was analyzed by real-time qPCR. (C) Immunoblotting for CTSB/L protein levels in 
CHIP-hi vs. CHIP-lo BT474 cells. (D) CTSB/L activities in CHIP-hi vs. CHIP-lo 21MT1 
cells analyzed by the production of a red fluorescent cleavage product. (E, F) 
Quantification of CTSB (E) and CTSL (F) activities presented in D. Mean+/- S.D., n=10. 
(G) Degradation of FITC-labeled gelatin matrix (seen as black holes) by CHIP-lo vs. 
CHIP-hi 21MT1 cells seeded for 48 hours and stained for actin-containing invadopodia 
with phalloidin (red) and nuclei with DAPI (blue). (H) Quantification of gelatin 
degradation presented in G.  Mean +/- SD., n=4. 
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Figure 6. The CHIP-MZF1-CTSB axis also operates in triple-negative breast cancer 
cells. (A & B) CHIP-hi vs. CHIP-lo MDA-MB231 cells were analyzed by qPCR for 
CTSB/L mRNA (A) and immunoblotting for protein expression (B). (C) CTSB/L activity 
in CHIP-hi vs. CHIP-lo (MDA-MB231 cells analyzed as in Figure 4A. (D, E) 
Quantification of CTSB (D) and CTSL (E) activity shown in Figure D. Mean+ S.D., n=10. 
(F) FITC-gelatin degradation (black holes) in CHIP-hi vs. CHIP-lo MDA-MB231 cells. (G) 
Quantification of FITC-gelatin degradation. Mean +/- SD., n=6. 
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Figure 7. CTSB inhibition reduces ErbB2+ breast cancer cell tumorigenesis. (A) 21MT1 
cells cultured on FITC-gelatin were treated with DMSO or CTSB inhibitor (CA074; 25 
g/m l) for 48h  and  d egrad ation  analyzed  as in  Figu re 5G. (B) Quan tification  of FITC-
gelatin degradation shown in 7A. Mean + S.D., n=4. (C) 21MT1 cells seeded on Matrigel-
coated membranes were treated with DMSO (control) or CA074 (25 g/m l) for 24h , 
invaded cells stained with a fluorescent dye and quantified using a fluorescence reader. 
Mean + S.D., n=18. (D) FITC-gelatin degradation by MDA-MB-231 cells was analyzed 
after 48h culture in DMSO (control) or CTSB inhibitor (CA074; 25ug/ml) as in Figure 5G. 
(E) Quantification of FITC-gelatin degradation. Mean + S.D., n=4. (F) Invasion of MDA-
MB-231 cells incubated with DMSO (control) or CA074 (25 /m l) as in Fig. 6C. Mean + 
S.D., n=8. (G) Groups of nude mice carrying BT474 xenografts (average 0.5 cm3 size) 
received Trastuzumab (via tail vein; 4 mg/kg every 4 days) CA074 (i.p., 25 mg/kg in 
saline daily) or saline (control), and tumor volumes were monitored every other day. 
Mean +/- SEM., n=9. 
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Tables: 
Table 1: The association between Nuclear (N) CHIP and clinical-pathological 
variables in the whole patient cohort. 
Clinicopathological 
variables 
                                               N-CHIP 
         Negative/ low 
expression, N (%) 
High expression, N 
(%)                 
p-value 
Age (years) 
<50 
>50 
 
231(35.1%) 
426(64.9%) 
 
100(31.8%) 
214(68.2%) 
 
0.316 
Menopausal status 
Pre 
Post 
 
248(37.8%) 
409(62.2%) 
 
121(38.7%) 
192(61.3%) 
 
0.798 
Tumour Size 
<2 CM 
>2CM 
 
89(44.5%) 
361(55.5%) 
 
168(53.5%) 
146(46.5%) 
 
0.008 
Tumour Grade 
1 
2 
3 
 
66(10.2%) 
194(29.9%) 
388(59.9%) 
 
72(22.9%) 
126(40.1%) 
116(36.9%) 
 
1×10-7 
Tubule formation 
1 
2 
3 
 
23(3.7%) 
187(29.8%) 
417(66.5%) 
 
23(7.5%) 
117(38.1%) 
167(54.4%) 
 
4×10-4 
Pleomorphism 
1 
 
11(1.8%) 
 
6(2.0%) 
 
1×10-7 
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2 
3 
196(31.4%) 
418(66.9%) 
155(50.5%) 
146(47.6%) 
Mitosis 
1 
2 
3 
 
157(25.0%) 
117(18.7%) 
353(56.3%) 
 
148(48.2%) 
63(20.5%) 
96(31.3%) 
 
1×10-7 
Lymph Node Stage 
1 
2 
3 
 
398(61.4%) 
195(30.1%) 
55(8.5%) 
 
192(61.1%) 
101(32.2%) 
21(6.7%) 
 
0.558 
Lymphovascular 
invasion (LVI) 
No 
Definite 
 
 
418(64.5%) 
230(35.5%) 
 
 
202(64.5%) 
111(35.5%) 
 
 
0.993 
Nottingham 
Prognostic Index 
Mild 
Moderate 
High 
 
 
147(23.8%) 
368(59.5%) 
103(16.7%) 
 
 
126(41.7%) 
144(47.7%) 
32(10.6%0 
 
 
1×10-7 
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Table 2: The association between Nuclear (N) CHP and different proteins related to 
ER and HER2 pathways in the whole patient cohort. 
 
                                         N-CHIP 
 Negative/low 
expression, N (%) 
High expression, N (%) p-value 
        Hormone receptors 
   Oestrogen receptor 
(ER) 
Negative 
Positive 
 
207(31.7%) 
447(68.3%) 
 
44(14.2%) 
266(85.8%) 
 
1×10-7 
Progesterone receptor 
(PgR) 
Negative 
Positive 
 
296(47.0%) 
334(53.0%) 
 
97(32.1%) 
205(67.9%) 
 
1×10-5 
Androgen receptor 
(AR) 
Negative 
Positive 
 
272(6.5%) 
313(53.5%) 
 
65(23.7%) 
209(76.3%) 
 
1×10-7 
Triple negative (TN) 
status 
Non-TN 
TN 
 
497(78.1%) 
139(21.9%) 
 
276(89.9%) 
31(10.1%) 
1×10-5 
Basal phenotype 
Negative 
Positive 
 
528(82.8%) 
110(17.2%) 
 
285(92.5%) 
23(7.5%) 
5×10-5 
   Other ER related proteins 
CK7/8    
186 
 
Negative 
Positive 
12(1.9%) 
621(98.1%) 
3(1.0%) 
297(99.0%) 
0.310 
CK18 
Negative 
Positive 
 
2(16.2%) 
476(83.8%) 
 
22(7.9%) 
258(92.1%) 
 
0.001 
CK19 
Negative 
Positive 
 
63(10.2%) 
554(89.8%) 
 
16(5.4%) 
283(94.6%) 
 
0.014 
E-Cadherin 
Negative 
Positive 
 
235(38.1%) 
382(61.9%) 
 
104(35.0%) 
193(65.0%) 
 
0.368 
p-Cadherin 
Negative 
Positive 
 
229(43.8% 
294(56.2%) 
 
144(56.9%) 
109(43.1%) 
 
0.001 
N-Cadherin 
Negative 
Positive 
 
107(22.3%) 
372(77.7%) 
 
78(34.7%) 
147(65.3%) 
 
0.001 
 Tumour suppressor proteins 
p53 
Negative/low 
Positive 
 
423(67.9%) 
200(32.1%) 
 
228(77.3%) 
67(22.7%) 
 
0.003 
BRCA1 
Negative/low 
High 
 
 
266(52.3%) 
243(47.7%0 
 
87(34.0%) 
169(66.0%) 
 
2×10-6 
Proliferation markers    
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KI67-LI 
Negative/low 
High 
 
171(33.5%) 
339(66.5%) 
 
138(54.8%) 
114(45.2%) 
 
1×10-7 
Apoptosis related 
markers 
BCL2 
Negative/low 
High 
 
 
219(44.6%)  
272(55.4%)  
 
 
71(32.7%)  
146(67.3%)  
 
 
0.003 
       HER family proteins 
HER1 
Negative 
Positive 
 
482(76.0%)  
152(24.0%)  
 
254(83.6%)  
50(16.4%)  
 
0.009 
HER2 
Negative 
Positive 
 
521(82.6%)  
110(17.4%)  
 
273(90.7%)  
28(9.3%)  
 
0.001 
HER3 
Negative 
Positive 
 
44(7.5%)  
539(92.5%)  
 
30(10.8%)  
248(89.2%)  
 
0.112 
HER4 
Negative 
Positive 
 
65(10.4%)  
560(89.6%)  
 
50(16.4%)  
254(83.6%)  
 
0.009 
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Supplemental Table 1: The list of transcription factors whose DNA-binding activities 
were downregulated by CHIP overexpression in ErbB2+ BT474 cells.  
ACPBP E12/E47 L-lll BP NF-E6/CP1 
ADD-1 E2 Lactoferrin-BP NF-Y 
ADR-1 EGR-1 LF-A1 NFkB 
ALF-1 EKLF LSF p-53 
alpha-PAL ETF LXRF-1 PAX-2 
AML-1 Freac-2 MEF-1 PAX-4 
ARP Freac-4 MRE PAX-5 
ATF GAG MT-box PAX-6 
ATF adelta GBF-1/2/3/HY5 MTF PBGD BP 
ATF-a H4TF-1 MUSF-1 Pbx1 
c-Rel HFH-1 MyoD PCF 
CACC HFH-3 MZF1 PEBP-2 
CCAAT HFH-8 NF-1 PPUR 
CEBP HIF-1 NF-1/2 PPUR 
CEF-2 HNF-3 NF-4FA PRDll-BF1 
COUP-TF HNF-4a NF-Atx PUR 
CTCF ISGF NF-E1/YY1 RAR/DR-5 
E12 Isl-1 NF-E2 RB 
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Supplemental Table 2: The list of transcription factors whose DNA-binding activities 
were downregulated by CHIP overexpression in MDA-MB-231 cells.  
alpha-PAL Ets LF-A2 PTF-1b 
ACPBP Fast-1 LXRE-1 PU1 
AF-1 Fra-1/JUN LyF PUR 
AFP-1 GAG MAZ RIPE3a1 
AhR/Amt GATA-3 MDBP RORE 
ALF-1 GBF-1/2/3 MHC W box RREB 
AIC/CBF GKLF MEF-2a Skn 
AP-4 HEN-1 Myo D Sp-1 
ARP HFH-1 MZF1 SPERM-1 
ATF  HFH-8/3/LUN NF-1 SRF 
ATF adelta HFH-11B/11a NF-4FA Stat-1/3 
CACC HOX4C NFAT-1 Tat 
CBF HIF-1 NF-Y Tax/CREB 
CCAC HiNF-A OCT TFE3 
Cdx-2 HiNF-B ORE TF-LF 
CEBP HNF-1A P53 TGT-3 
c-myb BP ICSBP P55 TIF-1 
CP-1 Ikoros PAX-2 TREF-1/2 
CSBP IRF-1/2 PAX-5 URE 
CYBP1A1 ISGF PEBF WT1 
DE-1 KKLF PEPCK PR YB-1 
E2 Lacto-ferrin BP PO-B ZNF174 
EKLF LCR-F1 PPAR 
 
EGR-2 LH2/Lim-1 PPUR 
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Supplementary Figure S1. Validate the antibody-based CHIP staining in vitro and in 
vivo. (A) Western blotting showed endogenous and exogenous CHIP expression in 
breast cancer cell lines. Hsc70 was used as loading control. (B) CHIP IHC staining in 
MCF7 CHIP-hi (control shRNA), CHIP-low (CHIP shRNA) and MDA-MB-231cells. 
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Supplementary Figure S2. CHIP expression level in breast cancer cell lines. (A) Real-
time QPCR analysis shows reduced CHIP mRNA expression in ErbB2+ and triple 
negative breast cancer cell lines comparing with ER+ breast cancer cell lines. GAPDH 
was used as control. (B) Western blotting showed reduced CHIP protein expression in 
ErbB2+ and triple negative breast cancer cell lines comparing with ER+ breast cancer cell 
lines. Hsc70 was used as loading control. C) Western blotting showed reduced CHIP 
protein expression in most ErbB2+ and triple negative PDX samples. Hsc70 was used as 
loading control. (D) Analyses of CHIP, ErbB2, TN status in commercial TMA (BR20837, 
from US Biomax) 
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Supplementary Figure S3. CHIP-dependent reduction of tumor volume and 
metastasis in MDA-MB-231 xenograft model. (A) Representative tumor, liver and lung 
organs from MDAMB-231 CHIP-lo (MSCV-puro) and CHIP-hi (MSCV-CHIP) xenograft. 
(B) Live and lung metastasis from MDA-MB-231 CHIP-lo (MSCV-puro) and CHIP-hi 
(MSCV-CHIP) xenograft were summarized. 
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Supplementary Figure S4. MZF1/Cathepsin B expression is regulated by CHIP in 
MCF7. (A) Real-time QPCR analysis shows reduced MZF1 mRNA expression in MCF7 
CHIP-hi (control shRNA) comparing with CHIP-lo (CHIP shRNA) cells. GAPDH was 
used as control. (B) Western blotting showed reduced cathepsin B protein expression in 
MCF7 CHIP-hi (control shRNA) comparing with CHIP-lo (CHIP shRNA) cells. Hsc70 
was used as loading control.  
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Detailed Materials and Methods (Supplementary) 
Antibodies and Reagents: Antibodies used for immunoblotting were as follows: 
Ubiquitin (mouse monoclonal P4D1; Cat. 3936S, Cell signaling, Denver, PA); ErbB2 
(mouse monoclonal; Cat. 554299, BD-Pharmingen, San Jose, CA); MZF1 (mouse 
monoclonal; Cat. SAB1402398, Sigma Aldrich, St. Louis, MO); Cathepsin B (rabbit 
monoclonal; Cat. Ab125067, Abcam, Cambridge, MA); and HSC70 (B-6 antibody; Cat. sc-
7298, Santa Cruz Biotechnology, Santa Cruz, CA). Rabbit anti-CHIP antibody used for 
blotting has been described (1).A second rabbit antibody (Cat. PA5-29024, Thermo 
Scientific, Waltham, MA) was used for IHC staining of CHIP. Secondary antibodies for 
immunoblotting included horseradish peroxidase (HRP)-conjugated Protein A or HRP-
conjugated rabbit anti-mouse antibody (Invitrogen, Carlsbad, CA). 
Cell Lysates: Cells were either lysed in RIPA lysis buffer (50 mM Tris pH 7.5, 150 mM 
NaCl, 1% Triton-X-100, 0.05% deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 10 mM NaF, and 1 mM sodium orthovanadate) or Triton-X-100 lysis 
buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% Triton-X-100, 1 mM PMSF, 10 mM NaF, 
and 1 mM sodium orthovanadate)(2). Lysates were rocked at 4°C for at least 1 hour, 
centrifuged at 13,000 rpm for 20 minutes at 4°C and the supernatants assayed for protein 
concentration using the BCA assay kit (Thermo Fisher Scientific, Rockford, IL) or the 
Bradford assay (Bio-Rad Laboratories, Hercules, CA). 
Immunoprecipitation: 1 mg of RIPA lysates and an optimized amount of the indicated 
antibody was rocked overnight at 4°C. 200 µl of 10% Protein A Sepharose (GE 
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Healthcare, Chalfont St. Giles, UK) beads (washed with RIPA buffer) were added to 
each IP sample and rocked at 4°C overnight. The beads were washed five times with 
RIPA buffer and bound proteins resolved by SDS-Polyacrylamide (Biorad) Gel 
Electrophoresis (PAGE), transferred to Polyvinylidene fluoride (PVDF) membrane (Bio-
Rad Laboratories, Hercules, CA) and subjected to Western Blotting(1). 
RNA extraction and real-time PCR: The total RNA was extracted using TRIzol reagent 
(Invitrogen), reverse transcribed using Quantitative real-time PCR kit (cat. 204141, 
Qiagen, Germantown, MD) was performed using the following primers: (a) MZF1 
forward primer 5’-CGTAGAGAAGTGAGGAAA-3’ and reverse primer 5’-
ATGATCAGGTCATACTCC-3’; (b) CTSB forward primer 5’-
AACCACAGGCTGGGATGTAG-3’ and reverse primer 5’-
CACTGACTGGGGTGACAATG-3’; (c) CTSL forward primer 5’-
GATGGAGGAGAGCAGTGTGG-3’and reverse primer 5’-
GCACTAAAAGCCCAACAAGAAC-3’; (d) GAPDH forward primer 5’-
CCACTCCTCCACCTTTGAC-3’ and reverse primer 5’-ACCCTGTTGCTGTAGCCA-3’. 
Transfection Reagents and Plasmids: XtremeGENE 9 transfection reagent was from 
Roche Applied Science (Indianapolis, IN). A pMSCV expression construct encoding the 
Myc- epitope-tagged full-length CHIP protein (amino acids 1–303) was generated as 
described preciously(3).  
Cumulative proliferation assay: Cells were seeded in 6-well plates at 5,000 cells per 
well, counted after seven-day culture and re-plated in fresh 6-well plates at the original 
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plating density for a total of five serial passages. The cumulative cell numbers were 
calculated based on the fractions of each harvest used for replating and plotted as a 
function of the overall time in culture. 
Anchorage-independent growth assay: 2,500 cells were seeded in 0.35% soft agar on top 
of 0.6% soft agar layer in 6-well plates. After two weeks, cells were stained with crystal 
violet and imaged under a phase contrast microscope. The colonies from the whole wells 
were enumerated using Image J (NIH, MD). All experiments were done in triplicates, 
and repeated three times. 
 Transwell migration and invasion assays: The cells were seeded in the top chamber of 
transwell chambers with 8 µm pore size nitrocellulose filters (Corning) in serum-free 
medium. Medium containing 10% FBS served as a chemoattractant in the lower 
chamber. For the invasion assay, the membranes were coated with 1:2 diluted Matrigel 
(BD Biosciences) before seeding the cells. After 24 h, the cells on the upper side of the 
membrane were removed by scraping with cotton swabs, while those on the lower side 
were fixed with methanol, stained with crystal violet and cells were counted. 
Experiments were run in triplicates and repeated thrice. For invasion assay in Figure 7, 
cells were seeded in top chambers of 96-well invasion chambers coated with Matrigel 
(CytoSelect™ 96-well Cell Invasion Assay Kit; Cat. CBA112, Cell Biolabs, INC.) followed 
by analyses as in migration assays. 
Extracellular matrix degradation assay: This assay was carried out using QCM™ 
Gelatin Invadopodia kit (Cat. ECM670, EMD Millipore, Billerica, MA) according to the 
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manufacturer’s protocol. FITC-labeled gelatin was coated onto glass chamber slides and 
crosslinked with 0.5% glutaraldehyde in PBS for 30 minutes. Slides were then washed 
three times each with PBS and 50 mM glycine in PBS. Cells were cultured for various 
time points to allow ECM degradation, seen as focal loss of fluorescent signal (“holes”) 
in the labeled gelatin layer. Experiments were run in replicates and repeated thrice. Six 
fields per chamber were imaged and the fluorescence intensity was further analyzed 
using Image J (NIH).  
In vivo xenograft experiment: 10 million cells mixed with 0.2 ml Matrigel (BD 
Biosciences) were implanted in the mammary fat pad of 4-6 week old non-pregnant 
female NSG mice (The Jackson Laboratory).  Three days prior to cell implantation, the 
mice were primed with s/c estrogen pellet (0.72 mg/ 60 day pellets; Innovative Research 
of America, Sarasota, FL). Tumor growth was monitored weekly for 10 weeks.  Tumor 
dimensions were measured with Vernier calipers and tumor volume calculated as length 
x width x depth/2.  Mice were euthanized when control tumors reached 2 cm3 in volume 
or showed signs of ill health, as per institutional IACUC guidelines. At the end of the 
experiment the tumor, as well as liver and lung, are resected, and formalin-fixed and 
paraffin-embedded for further analyses.  
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